WO2024107410A1 - Cd39 selection for cytotoxicity of genetically engineered t regulatory cells - Google Patents
Cd39 selection for cytotoxicity of genetically engineered t regulatory cells Download PDFInfo
- Publication number
- WO2024107410A1 WO2024107410A1 PCT/US2023/037215 US2023037215W WO2024107410A1 WO 2024107410 A1 WO2024107410 A1 WO 2024107410A1 US 2023037215 W US2023037215 W US 2023037215W WO 2024107410 A1 WO2024107410 A1 WO 2024107410A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- car
- population
- cell
- treg
- Prior art date
Links
- 210000003289 regulatory T cell Anatomy 0.000 title claims abstract description 82
- 230000003013 cytotoxicity Effects 0.000 title claims abstract description 22
- 231100000135 cytotoxicity Toxicity 0.000 title claims abstract description 22
- 101150117736 Entpd1 gene Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 234
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 130
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims abstract description 83
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 48
- 239000000427 antigen Substances 0.000 claims abstract description 47
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 230000002829 reductive effect Effects 0.000 claims abstract description 10
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 39
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 39
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 26
- 208000024908 graft versus host disease Diseases 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 12
- 206010052779 Transplant rejections Diseases 0.000 claims description 11
- 230000007423 decrease Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 abstract description 14
- 231100000433 cytotoxic Toxicity 0.000 abstract description 10
- 239000003550 marker Substances 0.000 abstract description 6
- 230000002902 bimodal effect Effects 0.000 abstract description 2
- 231100000050 cytotoxic potential Toxicity 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 47
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 37
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 24
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 24
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 24
- 230000027455 binding Effects 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 108010075704 HLA-A Antigens Proteins 0.000 description 20
- 239000003153 chemical reaction reagent Substances 0.000 description 19
- 108700028369 Alleles Proteins 0.000 description 18
- 230000001086 cytosolic effect Effects 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 230000011664 signaling Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 11
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 11
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 11
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 11
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 10
- 238000002617 apheresis Methods 0.000 description 10
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 108091008874 T cell receptors Proteins 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 7
- 208000024340 acute graft versus host disease Diseases 0.000 description 7
- 230000000735 allogeneic effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108010058607 HLA-B Antigens Proteins 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 210000002501 natural regulatory T cell Anatomy 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 5
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 210000004153 islets of langerhan Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000010187 selection method Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000961 alloantigen Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000002602 induced regulatory T cell Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 3
- 239000012114 Alexa Fluor 647 Substances 0.000 description 3
- -1 CD3^ Proteins 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- 108010052199 HLA-C Antigens Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000006461 physiological response Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101710142296 HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 description 2
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 description 2
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 240000007019 Oxalis corniculata Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 2
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000020385 T cell costimulation Effects 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 2
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 230000020955 B cell costimulation Effects 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 108010080422 CD39 antigen Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 101150090209 HCST gene Proteins 0.000 description 1
- 102210042925 HLA-A*02:01 Human genes 0.000 description 1
- 108010080347 HLA-A*26 antigen Proteins 0.000 description 1
- 108010041379 HLA-A*30 antigen Proteins 0.000 description 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
- 108010018475 HLA-A31 antigen Proteins 0.000 description 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101100274557 Heterodera glycines CLE1 gene Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000993380 Homo sapiens Hypermethylated in cancer 1 protein Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000603882 Homo sapiens Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 102100031612 Hypermethylated in cancer 1 protein Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000008193 Interleukin-2 Receptor beta Subunit Human genes 0.000 description 1
- 108010060632 Interleukin-2 Receptor beta Subunit Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 230000035986 JAK-STAT signaling Effects 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001678 brown HT Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000012965 maculopapular rash Diseases 0.000 description 1
- GRPSNTXTTSBKGW-BVGHQBMWSA-J magnesium;potassium;sodium;(3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;triacetate;chloride Chemical compound [Na+].[Mg+2].[Cl-].[K+].CC([O-])=O.CC([O-])=O.CC([O-])=O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O GRPSNTXTTSBKGW-BVGHQBMWSA-J 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 229940065199 normosol-r Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Definitions
- Tregs are a specialized subpopulation of T cells that act to suppress immune response, thereby maintaining homeostasis and self-tolerance. It has been shown that Tregs are able to inhibit T cell proliferation and cytokine production and play a critical role in preventing autoimmunity. Different subsets with various functions of Treg cells exist. Tregs can be usually identified by flow cytometry. The most specific marker for these cells is FoxP3, which is localized intra-cellularly. Dysregulation in Treg cell frequency or functions may lead to the development of autoimmune disease. Therapeutic Treg modulation is being developed to treat certain immune disorders, for example to prevent graft v host disease, or allograft rejection.
- Treg Promising results of initial studies using Treg as a clinical intervention have increased interest in this type of the cellular therapy. As such, methods of isolation and expansion of Tregs have been studied and optimized. Further, preclinical studies have shown antigenspecific Tregs may be more efficient due to their homing ability towards the cognate antigen. Antigen specificity can be conferred to regulatory T cells by transducing them with recombinant TCR. TCR-engineered T cells recognize peptides from both intracellular and surface derived proteins. Moreover, TCR-T cells have high affinity to cognate major histocompatibility complex (MHC)-peptide and induce a potent immune synapse formation. However, TCR-engineered Tregs are MHC dependent.
- MHC major histocompatibility complex
- Chimeric antigen receptor (CAR) technology offers a non-MHC- dependent approach.
- CAR-Treg cells utilize an extracellular antigen recognition domain from a single-chain variable fragment (scFv) of an antibody combined with an intracellular signaling domain.
- scFv single-chain variable fragment
- Many other creative receptor-targeted engineered fusion proteins are also being explored to direct and activate T regulatory cells to specific tissue or secreted targets. This combination allows for the construct to activate a T-cell response without interacting with the antigen in the context of MHC.
- T regulatory cells can also be present in T cell cultures for CAR T cells expanded and transduced for cancer targeting such as targeting B cells through CD19.
- T regulatory cells in bulk are less effective in general in cytotoxic killing of target cancer and may affect the success of CAR T therapy by interfering with conventional T cells mediating anti-cancer responses. Subsets that do not mediate cytotoxic killing but are immunoregulatory may contribute exceptionally to reducing the efficacy of CAR T therapy. Likewise, subsets of T regulatory cells that are cytotoxic may be preferred as CAR T therapeutics because they are likely to function when CD8 or other T cell subsets become exhausted, anergic or otherwise hyper-activated and lose efficacy.
- compositions and methods are provided herein relating to Treg cells modified by introduction of a chimeric antigen receptor (CAR), referred to herein as CAR-Treg cells.
- CAR chimeric antigen receptor
- the CAR selectively binds to an antigen present on a target cell population. It is shown herein that populations of CAR-Treg cells are bimodal with respect to expression of the surface marker CD39; and that the cytotoxic potential of the cell population segregates with respect to such CD39 expression. Selection for a CD39 + CAR-Treg population provides for a population with significantly reduced cytotoxic risk toward the cell population targeted by the CAR, and may improve immunoregulatory function.
- CD39 + CAR-Treg cell populations are useful in the treatment of conditions where it is desirable for the Treg cells to enhance immune tolerance, e.g. in the treatment of autoimmune disease, to reduce graft v host disease, to provide tolerance in transplantation, to promote wound healing or tissue regeneration and the like.
- selection for a CD39' CAR-Treg population provides for a population with enhanced cytotoxicity toward the cell population targeted by the CAR deleting antigen, which can find use in depletion of targeted populations, e.g. in cancer, depletion of undesirable antigen- presenting cells such as those present in transplantation rejection, autoimmune or inflammatory diseases, and the like.
- a composition is provided of CAR-Treg cells with reduced cytotoxic activity against the CAR-targeted cell population, relative to the unselected CAR-Treg population from which it is derived.
- the CAR-Treg cells are characterized by CD39 expression, i.e. the cells are CD39 + .
- the reduction in cytotoxicity may be measured, e.g. by an assay for apoptosis of target cells, where the reduction is at least 25%, at least 50%, at least 75% decrease, and may be a two-fold decrease or greater decrease in cytotoxicity relative to an unselected population.
- the cell population may be provided as a composition suitable for therapeutic administration.
- a therapeutic composition may comprise a therapeutically effective dose of CD39 + CAR-Treg cells, in a physiologically acceptable excipient.
- a composition is provided of CAR-Treg cells with enhanced cytotoxic activity against the CAR-targeted cell population, relative to the unselected CAR- Treg population from which it is derived.
- the CAR-Treg cells are characterized low levels or the absence of CD39 expression.
- the enhancement in cytotoxicity may be measured, e.g. by an assay for apoptosis of target cells, where the enhancement is at least 25%, at least 50%, at least 75% increase, and may be a two-fold increase or greater in cytotoxicity, relative to unselected cells.
- the cell population may be provided as a composition suitable for therapeutic administration.
- a therapeutic composition may comprise a therapeutically effective dose of CD39" CAR-Treg cells, in a physiologically acceptable excipient.
- CD39- CAR Treg cells can regain some CD39+ expression with ex vivo cell culture expansion but retain the ability to have increased cytotoxicity.
- a method of treating an individual with a therapeutically effective dose of CAR-Treg cells or other genetically modified Treg cells, e.g. T cell receptor transduced cells comprising administering to an individual in need thereof an effective dose of a population of genetically modified Treg cells, e.g. CAR-Treg cells that have been selected based on CD39 expression.
- Conditions where the cells are used may include, for example, GVHD, type 1 diabetes, autoimmunity, wound healing, tissue regeneration and transplantation tolerance.
- methods of treating or inhibiting autoimmune disease, allergic disease, or inflammatory disease in a patient in need thereof comprising administering an effective dose of a CD39 selected CAR-Treg cell population to an individual in need there.
- methods of reducing transplant rejection in a patient transplanted with hematopoietic stem cells, bone marrow cells, or a solid organ comprising administering an effective dose of a CD39 selected CAR-Treg cell population to an individual in need there.
- a method for the in vitro culture and genetic modification of T cells to generate a population of CAR-Treg cells with reduced cytotoxic activity against the CAR-targeted cell population.
- An initial T cell population is isolated from a donor, which may be allogeneic or autologous relative to the recipient.
- the T cells may be a population comprising CD4 + T cells, optionally a population selected for Treg cells.
- the cells can be engineered by transducing with CAR constructs and FoxP3 coding sequences. Treg populations are transduced with CAR constructs but do not require FoxP3.
- the population is sorted based on expression of CD39, e.g.
- CD39 selected, CAR-Treg cells may be expanded in culture, activated, cryopreserved, and the like.
- FIG. 1 Co-culture of human CAR Treg targeting human islets in cell culture. Cytotoxic killing of islets can occur as identified by flow cytometric assessment of annexin V and 7AAD in human islet beta cells specifically. Unselected Tregs from HLA-A2 negative donors identified as CD4+CD25+CD17lo were culture expanded and transduced with CAR construct with A2-specific scFv and CD3zeta and CD28 internal stimulatory domain.
- the HLA-A2 specific CAR Treg specifically caused a decrease in the number of normal healthy islet beta cells that did not express Annexin V or incorporate 7 AAD (normalized to islets in cell culture alone as), as compared to untransduced Treg (mock), or Treg with irrelevant scFv binding domains (1 X9Q that binds FITC) and FRB which binds a myeloid-specific cell surface marker.
- FIG. 3 When looking at ex vivo culture expanded total Treg as a whole, those CAR Treg with the lowest CD39 expression had the highest cytotoxic activity as measured by islet cell death.
- FIG. 4. CD39+ Treg show distinct features cmTreg: the cells of this weakly proliferating population circulate between secondary lymphoid organs and express anti-apoptotic factors Bcl-2 and Mcl-1 at a high level. Not prone to apoptosis, great potential to have a longer in vivo survival time after injection.
- FIG. 5 CD39+ Treg show more stable and higher FOXP3 expression and more phenotypic stability in cell culture expansion compared to CD39-
- FIG. 6 CD39+ expanded Tregs have statistically lower expression of granzyme when compared to bulk/whole Treg versus CD39- Treg. The difference in the ratio of central memory to effector memory in these cells becomes more pronounced after expansion.
- FIG. 7. CD39 Treg have higher LAG3 expression, suggesting a more suppressive phenotype.
- 3lox5 cells were derived from purified adult pancreatic beta cells and microscopic evaluation confirms HLA-A2 CAR Treg mediate cytotoxic killing of tissue targets.
- FIG. 9. Primary pancreatic islet cells were derived from purified adult pancreatic beta cells and microscopic evaluation confirms HLA-A2 CAR Treg mediate cytotoxic killing of tissue targets.
- FIG. 10 A2 CAR CD39 negative T reg cells directly induce islet cytolysis.
- FIG. 1 A2 CAR Treg that are CD39+ preserve glucose-stimulated insulin secretion in target organs, versus CD39- cells that had reduced islet functionality.
- the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- the term “about” or “approximately” refers a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length ⁇ 15%, ⁇ 10%, ⁇ 9%, ⁇ 8%, ⁇ 7%, ⁇ 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, or ⁇ 1 % about a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- isolated means material that is substantially or essentially free from components that normally accompany it in its native state.
- obtained or “derived” is used synonymously with isolated.
- subject refers to a vertebrate, preferably a mammal, more preferably a human. Tissues, cells, and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed.
- treatment includes any beneficial or desirable effect, and may include even minimal improvement in symptoms.
- Treatment does not necessarily indicate complete eradication or cure of the disease or condition, or associated symptoms thereof.
- prevention indicates an approach for preventing, inhibiting, or reducing the likelihood of a symptom of disease. It also refers to delaying the onset or recurrence of a disease or condition or delaying the occurrence or recurrence of the symptoms of a disease. As used herein, “prevention” and similar words also includes reducing the intensity, effect, symptoms and/or burden of disease prior to onset or recurrence.
- the term “amount” refers to “an amount effective” or “an effective amount” is the dose of a cell population that achieves a beneficial or desired prophylactic or therapeutic result, including clinical results.
- a “therapeutically effective amount” of a cell population may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the virus or cell to elicit a desired response in the individual.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the cell are outweighed by the therapeutically beneficial effects.
- the term “therapeutically effective amount” includes an amount that is effective to “treat” a subject (e.g., a patient).
- An “increased” or “enhanced” amount of a physiological response is typically a “statistically significant” amount, and may include an increase that is 1.1 , 1 .2, 1 .5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1 , e.g., 1.5, 1.6, 1 .7. 1 .8, etc.) the level of activity in an untreated cell.
- a “decrease” or “reduced” amount of a physiological response is typically a “statistically significant” amount, and may include an decrease that is 1.1 , 1 .2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1 , e.g., 1 .5, 1 .6, 1 .7. 1 .8, etc.) the level of activity in an untreated cell.
- maintain or “preserve,” or “maintenance,” or “no change,” or “no substantial change,” or “no substantial decrease” refers generally to a physiological response that is comparable to a response caused by either vehicle, or a control molecule/cell composition.
- a comparable response is one that is not significantly different or measurable different from the reference response.
- exogenous is used herein to refer to any molecule, including nucleic acids, protein or peptides, small molecular compounds, and the like that originate from outside the organism.
- endogenous refers to any molecule that originates from inside the organism (i.e., naturally produced by the organism).
- Tregs are a specialized subpopulation of T cells that can suppress activation of the immune system and thereby maintain immune tolerance.
- Tregs are share the phenotype of being CD4 + CD25 + FOXP3+.
- 3+CD4+ regulatory T cells which include natural regulatory T cells (nTregs) and induced regulatory T cells (iTregs).
- nTregs are T cells produced in the thymus and delivered to the periphery as a long-lived lineage of self-antigen-specific lymphocytes.
- iTregs are recruited from circulating lymphocytes and acquire regulatory properties under particular conditions of stimulation in the periphery.
- nTregs and iTregs are CD4+CD25+; both can inhibit proliferation of CD4+CD25- T cells in a dose-dependent manner, and both are anergic and do not proliferate upon TOR stimulation.
- Tregs can be identified or selected based on various marker expression profiles.
- Non-limiting examples of marker expression profiles that can be used to select Tregs include (1 ) CD4+CD25+CD127dim, (2) CD4+FOXP3+, (3) CD3+CD4+CD25+, (5) CD3+ CD4+ CD25+ CD127dim, (6) CD3+ CD4+ CD25+ CD127dim F0XP3+, (7) CD3+FOXP3+, (8) CD3+CD4+FOXP3+, (9) CD3+ CD4+CD25+FOXP3+, (10) CD3+CD25+FOXP3+, (11 ) CD3+CD25+CD127dim, (12) CD4+CD25+, (13)
- the Treg cells are CD4 + CD25 + CD127 lo FoxP3 + Treg. Selection based on certain expression profiles can be achieved based on extracellular markers and without requiring cell permeabilization, for example, selection based on CD4+CD25+CD127 10 phenotype.
- a T cell e.g. a CD4+ T cell
- a T cell is engineered to express FoxP3 to achieve a Treg phenotype.
- Foxp3 plays a crucial role in development and function of Treg cells. Constructs and methods from expressing Foxp3 in T cells are described in, for example, WO 2007/065957, which is incorporated herein in its entirety.
- the Foxp3 is wild-type (WT) Foxp3. Exemplary wild type human Foxp3 sequences are described in NP_054728.2, the contents of which are incorporated herein by reference.
- the Foxp3 is a minimal Foxp3.
- a “minimal Foxp3” is engineered to mimic N-terminally, C-terminally, or N-and C-terminally cleaved Foxp3 forms, see for example WO2019241549A1 , herein specifically incorporated by reference.
- a minimal FOXP3 may be truncated to start at residue 52 relative to the wild-type protein, and to end at residue 413 (relative to Genbank NP_054728.2).
- Minimal Foxp3 is, in some contexts, more active than wild-type (WT) Foxp3.
- the minimal Foxp3 comprises a Foxp3 polypeptide that has been N-terminally truncated, C-terminally truncated, or N- and C- terminally truncated. In some embodiments, the Foxp3 is constitutively active.
- a polynucleotide encoding the CAR and the polynucleotide encoding the Foxp3 are configured for translation as a fusion protein comprising the CAR and the Foxp3.
- the CAR polynucleotide may be 5’ to the Foxp3 polynucleotide, in which case the CAR is expressed as a N-terminal fusion to the Foxp3, or vice-versa.
- the CAR is N-terminal to the Foxp3 in the fusion protein.
- the fusion protein comprises a cleavage site between the CAR and the Foxp3.
- the cleavage site is a 2 A peptide.
- the Treg T-cell is modified to surface express a chimeric antigen receptor (a CAR- Treg cell).
- a CAR- Treg cell a chimeric antigen receptor
- the terms “chimeric antigen receptor T-cell” and “CAR-Treg cell” are used interchangeably to refer to a T-cell that has been recombinantly modified to express a CAR.
- chimeric antigen receptor and “CAR” are used interchangeably to refer to a polyprotein comprising multiple functional domains arranged from amino to carboxy terminus in the sequence: (a) an antigen binding domain (ABD), (b) a transmembrane domain (TD); (c) one or more cytoplasmic signaling domains (CSDs) wherein the foregoing domains (a) - (c) may optionally be linked by one or more spacer domains.
- the CAR may also further comprise a signal peptide sequence which is conventionally removed during post-translational processing and presentation of the CAR on the cell surface.
- CARs useful in the practice of the present invention are prepared in accordance with principles well known in the art.
- CAR constructs are commonly accomplished through viral vector systems such as lentivirus, Gamma-retroviral, and adeno-associated viral (AAV) vectors. Additionally, viral-free systems such as the Sleeping Beauty (SB), or piggyBac transposon have been used to integrate CAR encoding DNA with favorable integration into the target genome. Furthermore, Clustered regularly interspaced short palindromic repeats (CRISPR)- CRISPR associated protein 9 (Cas9) gene-editing technology, which allows for the insertion of DNA at specific locations directed by RNA, has also been used to engineer CAR T cells. CRISPR-engineered CAR T cells, which express CAR from an endogenous TCR locus remain active for longer periods than their virus-transduced counterparts.
- CRISPR Clustered regularly interspaced short palindromic repeats
- Cas9 CRISPR associated protein 9
- antigen binding domain refers to a polypeptide that specifically binds to an antigen expressed on the surface of a target cell.
- the ABD may be any polypeptide that specifically binds to one or more antigens expressed on the surface of a target cell.
- the ABD is a single chain Fv (ScFv).
- ScFv is a polypeptide comprised of the variable regions of the immunoglobulin heavy and light chain of an antibody covalently connected by a peptide linker (Bird, et al. (1988) Science 242:423-426; Huston, et al. (1988) PNAS(USA) 85:5879-5883; S-z Hu, et al. (1996) Cancer Research, 56, 3055-3061 .
- the generation of ScFvs based on monoclonal antibody sequences is well known in the art. See, e.g. The Protein Protocols Handbook, John M. Walker, Ed.
- Antibodies used in the preparation of scFvs may be optimized to select for those molecules which possess particular desirable characteristics (e.g. enhanced affinity) through techniques well known in the art such as phage display and directed evolution.
- the ABD comprises an anti-CD19 scFv, an anti-PSA scFv, an anti- HER2 scFv, an anti-CEA scFv, an anti-EGFR scFv, an anti-EGFRvlll scFv, an anti-NY-ESO- 1 scFv, an anti-MAGE scFv, an anti-5T4 scFv, or an anti-Wnt1 scFv.
- the ABD is a single domain antibody obtained through immunization of a camel or llama with a target cell derived antigen, in particular a tumor antigen. See, e.g.
- the ABD may be generated wholly synthetically through the generation of peptide libraries and isolating compounds having the desired target cell antigen binding properties in substantial accordance with the teachings or Wigler, et al. United States Patent No. 6303313 B1 issued November 12, 1999; Knappik, et al., United States Patent No 6,696,248 B1 issued February 24, 2004, Binz, et al. (2005) Nature Biotechnology 23:1257-1268, and Bradbury, et al. (2011 ) Nature Biotechnology 29:245-254.
- the CARs of the present disclosure comprise a target-specific binding element otherwise referred to as an antigen binding moiety.
- the choice of moiety depends upon the type and number of ligands that define the surface of a target cell.
- the antigen binding domain may be chosen to recognize a ligand that acts as a cell surface marker on target cells associated with a particular disease state.
- examples of cell surface markers that may act as ligands for the antigen moiety domain in the CAR of the invention include those associated with autoimmune disease, transplant rejection, and the like.
- the CAR targets specific alleles of components of the Major Histocompatibility Complex (MHC) through the extracellular domain.
- MHC Major Histocompatibility Complex
- the resulting CAR-Treg cells downregulate or suppress the immune response to alloantigens.
- an alloantigen refers to a genetically determined antigen present in some but not all subjects of a species and which is capable of inducing the production of an alloantibody by subjects which lack it.
- exemplary alloantigens that can lead to transplant rejection include, but are not limited to, ABO blood group and Rh blood group, MHC class I or MHC class II complexes, where allele mismatches in MHC I or MHC II are significant risk factors for transplant rejection or graft-versus-host disease.
- the CAR targets specific alleles of components of the Major Histocompatibility Complex (MHC) e.g., HLA class 1 alleles HLA-A1 , HLA-A2, HLA-A1 1 , HLA- B44, HLA-B27, HLA-C07 and HLA-C04.
- MHC Major Histocompatibility Complex
- the MHC is MHC class I or MHC class II.
- the CAR targets a human leukocyte antigen, e.g.
- HLA-A human leukocyte antigen A
- HLA-B human leukocyte antigen B
- HLA-C human leukocyte antigen C
- the CAR targets an allele of HLA-A.
- HLA-A allele is an HLA-A 1 , HLA-A2, HLA -Al I, HLA-A24, HLA-A26, HLA-A30, HLA-A31 , HLA-A34, HLA-A36, HLA-A66, HLA-A68 or HLA-A69 allele.
- the HLA-A allele is an HLA- A2 allele.
- Exemplary HLA-A2 alleles include, but are not limited to, HLA-A*2:0l, an HLA- A*2:02, HLA-A* 2: 03, HLA-A*2:05, HLA-A*2:06, HLA- A*2:07 or HLA-A*2:0l I .
- the extracellular domain of the CAR targets HLA-A*2:0l, an HLA-A* 2: 02, HLA-A* 2: 03, HLA-A*2:05, HLA-A*2:06, HLA-A*2:07 or HLA- A*2:0l I .
- the extracellular domain of the CAR targets HLA-A*02:01.
- the CAR targets an allele of HLA-B.
- HLA-B There are about 3,600 known variants of HLA-B, all of which are envisaged as within the scope of the disclosure.
- the CAR targets an allele of HLA-C.
- HLA-B There are about 2,400 known variants of HLA-B, all of which are envisaged as within the scope of the disclosure.
- CAR targets an allele of human leukocyte antigen A (HLA-A, major histocompatibility complex, class I, A), human leukocyte antigen B (HLA-B, major histocompatibility complex, class I, B).
- the ABD may have affinity for more than one target antigen.
- an ABD of the present invention may comprise chimeric bispecific binding members, i.e. have capable of providing for specific binding to a first target cell expressed antigen and a second target cell expressed antigen.
- Non-limiting examples of chimeric bispecific binding members include bispecific antibodies, bispecific conjugated monoclonal antibodies (mab) 2 , bispecific antibody fragments (e.g., F(ab) 2 , bispecific scFv, bispecific diabodies, single chain bispecific diabodies, etc.), bispecific T cell engagers (BiTE), bispecific conjugated single domain antibodies, micabodies and mutants thereof, and the like.
- Non-limiting examples of chimeric bispecific binding members also include those chimeric bispecific agents described in Kontermann (2012) MAbs. 4(2): 182-197; Stamova et al. (2012) Antibodies, 1 (2), 172-198; Farhadfar et al. (2016) Leuk Res. 49:13-21 ; Benjamin et al. Ther Adv Hematol. (2016) 7(3):142-56; Kiefer et al. Immunol Rev. (2016) 270(1 ):178-92; Fan et al. (2015) J Hematol Oncol. 8:130; May et al. (2016) Am J Health Syst Pharm. 73(1 ):e6-e13.
- the chimeric bispecific binding member is a bivalent single chain polypeptides. See, e.g. Thirion, et al. (1996) European J. of Cancer Prevention 5(6) :507-51 1 ; DeKruif and Logenberg (1996) J. Biol. Chem 271 (13)7630-7634; and Kay, et al. United States Patent Application Publication Number 2015/0315566 published November 5, 2015.
- a chimeric bispecific binding member may be a bispecific T cell engager (BiTE).
- a BiTE is generally made by fusing a specific binding member (e.g., a scFv) that binds an antigen to a specific binding member (e.g., a scFv) with a second binding domain specific for a T cell molecule such as CD3.
- a chimeric bispecific binding member may be a CAR T cell adapter.
- CAR T cell adapter is meant an expressed bispecific polypeptide that binds the antigen recognition domain of a CAR and redirects the CAR to a second antigen.
- a CAR T cell adapter will have to binding regions, one specific for an epitope on the CAR to which it is directed and a second epitope directed to a binding partner which, when bound, transduces the binding signal activating the CAR.
- Useful CAR T cell adapters include but are not limited to e.g., those described in Kim et al. (2015) J Am Chem Soc. 137(8):2832-5; Ma et al. (2016) Proc Natl Acad Sci U S A. 1 13(4):E450-8 and Cao et al. (2016) Angew Chem Int Ed Engl. 55(26) :7520-4.
- a linker polypeptide molecule is optionally incorporated into the CAR between the antigen binding domain and the transmembrane domain to facilitate antigen binding.
- the linker is the hinge region from an immunoglobulin, e.g. the hinge from any one of IgG 1 , lgG2a, lgG2b, lgG3, lgG4, particularly the human protein sequences. Alternatives include the CH2CH3 region of immunoglobulin and portions of CD3. In those instances where the ABD is an scFv, an IgG hinge is effective.
- the linker comprises the amino acid sequence (G4S) n where n is 1 , 2, 3, 4, 5, etc., and in some embodiments n is 3.
- CARs useful in the practice of the present invention further comprise a transmembrane domain joining the ABD (or linker, if employed) to the intracellular cytoplasmic domain of the CAR.
- the transmembrane domain is comprised of any polypeptide sequence which is thermodynamically stable in a eukaryotic cell membrane.
- the transmembrane spanning domain may be derived from the transmembrane domain of a naturally occurring membrane spanning protein or may be synthetic. In designing synthetic transmembrane domains, amino acids favoring alpha-helical structures are preferred.
- Transmembrane domains useful in construction of CARs are comprised of approximately 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 22, 23, or 24 amino acids favoring the formation having an alpha-helical secondary structure.
- Amino acids having a to favor alpha-helical conformations are well known in the art. See, e.g Pace, etal. (1998) Biophysical Journal 75: 422-427.
- Amino acids that are particularly favored in alpha helical conformations include methionine, alanine, leucine, glutamate, and lysine.
- the CAR transmembrane domain may be derived from the transmembrane domain from type I membrane spanning proteins, such as CD3 ⁇ , CD4, CD8, CD28, etc.
- the cytoplasmic domain of the CAR polypeptide comprises one or more intracellular signal domains.
- the intracellular signal domains comprise the cytoplasmic sequences of the T-cell receptor (TCR) and co-receptors that initiate signal transduction following antigen receptor engagement and functional derivatives and sub-fragments thereof.
- TCR T-cell receptor
- a cytoplasmic signaling domain, such as those derived from the T cell receptor ⁇ -chain, is employed as part of the CAR in order to produce stimulatory signals for T lymphocyte proliferation and effector function following engagement of the chimeric receptor with the target antigen.
- cytoplasmic signaling domains include but are not limited to the cytoplasmic domain of CD27, the cytoplasmic domain S of CD28, the cytoplasmic domain of CD137 (also referred to as 4-1 BB and TNFRSF9), the cytoplasmic domain of CD278 (also referred to as ICOS), p110a, p, or 5 catalytic subunit of PI3 kinase, the human CD3 - chain, cytoplasmic domain of CD134 (also referred to as 0X40 and TNFRSF4), FceR1 y and chains, MB1 (Iga) chain, B29 (IgP) chain, etc.), CD3 polypeptides (5, A and E), syk family tyrosine kinases (Syk, ZAP 70, etc.), src family tyrosine kinases (Lek, Fyn, Lyn, etc.) and other molecules involved in T-cell transduction, such as CD2, CD5
- the CAR may also provide a co-stimulatory domain.
- co-stimulatory domain refers to a stimulatory domain, typically an endodomain, of a CAR that provides a secondary non-specific activation mechanism through which a primary specific stimulation is propagated.
- the co-stimulatory domain refers to the portion of the CAR which enhances the proliferation, survival or development of memory cells. Examples of costimulation include antigen nonspecific T cell co-stimulation following antigen specific signaling through the T cell receptor and antigen nonspecific B cell co-stimulation following signaling through the B cell receptor. Co-stimulation, e.g., T cell co-stimulation, and the factors involved have been described in Chen & Flies.
- the CSD comprises one or more of members of the TNFR superfamily, CD28, CD137 (4-1 BB), CD134 (0X40), Dap10, CD27, CD2, CD5, ICAM- 1 , LFA-1 (CD1 1 a/CD18), Lek, TNFR-I, TNFR-II , Fas, CD30, CD40 or combinations thereof.
- the intracellular domain of the CARs of the instant disclosure comprises an interleukin-2 receptor beta-chain (IL-2Rbeta or IL-2R-beta) cytoplasmic domain.
- the IL-2Rbeta domain is truncated.
- the IL- 2Rbeta cytoplasmic domain comprises one or more STAT5-recruitment motifs.
- the CAR comprises one or more STAT5-recruitment motifs outside the IL- 2Rbeta cytoplasmic domain.
- the IL-2R-beta cytoplasmic domain comprises one or more STAT5- recruitment motifs.
- STAT5 -recruitment motifs are provided by Passerini et al. (2008) STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25+ effector T cells.
- CARs are often referred to as first, second, third or fourth generation.
- the term first- generation CAR refers to a CAR wherein the cytoplasmic domain transmits the signal from antigen binding through only a single signaling domain, for example a signaling domain derived from the high-affinity receptor for IgE FcaRly, or the CD3 ⁇ J chain.
- the domain contains one or three immunoreceptor tyrosine-based activating motif(s) [ITAM(s)] for antigendependent T-cell activation.
- ITAM(s) immunoreceptor tyrosine-based activating motif(s)
- the ITAM-based activating signal endows T-cells with the ability to lyse the target tumor cells and secret cytokines in response to antigen binding.
- Second- generation CARs include a co-stimulatory signal in addition to the CD3T signal. Coincidental delivery of the delivered co-stimulatory signal enhances cytokine secretion and antitumor activity induced by CAR-transduced T-cells.
- the co-stimulatory domain is usually be membrane proximal relative to the CD3 ⁇ domain.
- Third-generation CARs include a tripartite signaling domain, comprising for example a CD28, CD3 ⁇ , 0X40 or 4-1 BB signaling region.
- fourth generation, or “armored car” CAR T-cells are further gene modified to express or block molecules and/or receptors to enhance immune activity.
- Examples of intracellular signaling domains comprising may be incorporated into the CAR of the present invention include (amino to carboxy): CD3 ⁇ ; CD28 - 41 BB - CD3 ⁇ ; CD28 - 0X40 - CD3 ; CD28 - 41 BB - CD3 ⁇ ; 41 BB -CD-28 - CD3 and 41 BB - CD3 ⁇ .
- CAR includes CAR variants including but not limited split CARs, ON-switch CARS, bispecific or tandem CARs, inhibitory CARs (iCARs) and induced pluripotent stem (iPS) CAR-T cells.
- split CARs refers to CARs wherein the extracellular portion, the ABD and the cytoplasmic signaling domain of a CAR are present on two separate molecules.
- CAR variants also include ON-switch CARs which are conditionally activatable CARs, e.g., comprising a split CAR wherein conditional hetero-dimerization of the two portions of the split CAR is pharmacologically controlled.
- CAR molecules and derivatives thereof i.e., CAR variants
- bispecific or tandem CARs refers to CARs which include a secondary CAR binding domain that can either amplify or inhibit the activity of a primary CAR.
- inhibitory chimeric antigen receptors or “iCARs” are used interchangeably herein to refer to a CAR where binding iCARs use the dual antigen targeting to shut down the activation of an active CAR through the engagement of a second suppressive receptor equipped with inhibitory signaling domains of a secondary CAR binding domain results in inhibition of primary CAR activation.
- Inhibitory CARs are designed to regulate CAR- T cells activity through inhibitory receptors signaling modules activation. This approach combines the activity of two CARs, one of which generates dominant negative signals limiting the responses of CAR-T cells activated by the activating receptor.
- iCARs can switch off the response of the counteracting activator CAR when bound to a specific antigen expressed only by normal tissues.
- iCARs-T cells can distinguish cancer cells from healthy ones, and reversibly block functionalities of transduced T cells in an antigen-selective fashion.
- CTLA- 4 or PD-1 intracellular domains in iCARs trigger inhibitory signals on T lymphocytes, leading to less cytokine production, less efficient target cell lysis, and altered lymphocyte motility.
- tandem CAR or “TanCAR” refers to CARs which mediate bispecific activation of T cells through the engagement of two chimeric receptors designed to deliver stimulatory or costimulatory signals in response to an independent engagement of two different tumor associated antigens.
- the chimeric antigen receptor T-cells are T-cells which have been recombinantly modified by transduction with an expression vector encoding a CAR in substantial accordance with the teaching above.
- a Treg cell, or a CD4+ T cells modified by introduction of a FoxP3 coding sequence may be used.
- T cells for engineering as described above are collected from a subject or a donor may be separated from a mixture of cells by techniques that enrich for desired cells, or may be engineered and cultured without separation.
- a population of cells comprising T regs can be isolated from whole blood.
- a population of cells comprising Tregs can be isolated from a peripheral blood apheresis product.
- a population of cells comprising Tregs can be isolated from a population of cells previously enriched and/or depleted for one or more other cell types, e.g., isolated from a population of cells depleted of CD34+ cells.
- Tregs are isolated from the flow-through fraction of a CD34+ MACS selection.
- the number of Tregs in a population of cells can be determined, for example, by flow cytometry, where Tregs can be identified as, for example, CD4+CD25+CD127 10 or CD4+FOXP3+. Dose calculations can be adjusted based on measures of cell viability measurements, e.g., viability determined via flow cytometry with propidium iodide or 7-AAD, or via trypan blue exclusion.
- An appropriate solution may be used for dispersion or suspension.
- Such solution will generally be a balanced salt solution, e.g. normal saline, PBS, Hank’s balanced salt solution, etc., conveniently supplemented with fetal calf serum or other naturally occurring factors, in conjunction with an acceptable buffer at low concentration, generally from 5-25 mM.
- Convenient buffers include HEPES, phosphate buffers, lactate buffers, etc.
- Techniques for affinity separation may include magnetic separation, using antibody-coated magnetic beads, affinity chromatography, cytotoxic agents joined to a monoclonal antibody or used in conjunction with a monoclonal antibody, e.g., complement and cytotoxins, and "panning" with antibody attached to a solid matrix, e.g., a plate, or other convenient technique.
- Techniques providing accurate separation include fluorescence activated cell sorters, which can have varying degrees of sophistication, such as multiple color channels, low angle and obtuse light scattering detecting channels, impedance channels, etc.
- the cells may be selected against dead cells by employing dyes associated with dead cells (e.g., propidium iodide).
- the affinity reagents may be specific receptors or ligands for the cell surface molecules indicated above.
- peptide-MHC antigen and T cell receptor pairs may be used; peptide ligands and receptor; effector and receptor molecules, and the like.
- the separated cells may be collected in any appropriate medium that maintains the viability of the cells, usually having a cushion of serum at the bottom of the collection tube.
- Various media are commercially available and may be used according to the nature of the cells, including dMEM, HBSS, dPBS, RPMI, Iscove’s medium, etc., frequently supplemented with fetal calf serum (FCS).
- FCS fetal calf serum
- FCS fetal calf serum
- the collected and optionally enriched cell population may be used immediately for genetic modification, or may be frozen at liquid nitrogen temperatures and stored, being thawed and capable of being reused.
- the cells will usually be stored in 10% DMSO, 50% FCS, 40% RPMI 1640 medium.
- the engineered cells comprise a complex mixture of immune cells, e.g., tumor infiltrating lymphocytes (TILs) isolated from an individual in need of treatment.
- TILs tumor infiltrating lymphocytes
- the engineered T cell is allogeneic with respect to the individual that is treated, e.g. see clinical trials NCT03121625; NCT03016377; NCT02476734; NCT02746952; NCT02808442. See for review Graham et al. (2016) Cells. 7(10) E155.
- an allogeneic engineered T cell is fully HLA matched. However not all patients have a fully matched donor and a cellular product suitable for all patients independent of HLA type provides an alternative.
- a universal ‘off the shelf’ CAR T cell product provides advantages in uniformity of harvest and manufacture.
- the Treg cells may be cultured in vitro under various culture conditions, as disclosed herein.
- the cell population may be conveniently suspended in an appropriate nutrient medium, such as TexMACS, Iscove’s modified DMEM, RPMI-1640, etc., and as disclosed herein are supplemented with human serum.
- the culture may contain activation agent factors to which the cells are responsive.
- Treg cells are usually obtained from a single donor, for example, obtained from mobilized peripheral blood apheresis of a single donor, although can be from combined donors.
- a donor and a recipient of the disclosure can be allogenic.
- a donor and a recipient of the cryopreserved cells can be HLA matched.
- a donor and a recipient of the of the cryopreserved cells can be HLA mismatched, e.g. mismatched at 1 , 2, 3, 4, 5, or 6 of the major HLA alleles.
- a donor and a recipient of the cryopreserved cells can be haploidentical.
- a cell population of the disclosure can be obtained from whole blood.
- a cell population of the disclosure can be obtained from a peripheral blood apheresis product, for example, a mobilized peripheral blood apheresis product.
- a cell population of the disclosure can be obtained from at least one apheresis product, two apheresis products, three apheresis products, four apheresis products, five apheresis products, six apheresis products, or more.
- CD39 ectonucleoside triphosphate diphosphohydrolase-1 , gene: ENTPD1 ; protein: NTPDasel
- CD39 is a cell surface enzyme with a catalytic site on the extracellular face, that catalyzes the hydrolysis of y- and
- the refseq for the human protein may be accessed at Genbank, NP_001091645, NP_001 157650, NP_001 157651 , NP_001 157653,
- Selection methods for cell populations can comprise methods involving positive or negative selection of a cell population of interest.
- Selection methods for cell populations can comprise affinity reagents, including but not limited to an antibody, a full-length antibody, a fragment of an antibody, a naturally occurring antibody, a synthetic antibody, an engineered antibody, a full-length affibody, a fragment of an affibody, a full-length affilin, a fragment of an affilin, a full-length anticalin, a fragment of an anticalin, a full-length avimer, a fragment of an avimer, a fulllength DARPin, a fragment of a DARPin, a full-length fynomer, a fragment of a fynomer, a full-length kunitz domain peptide, a fragment of a kunitz domain peptide, a full- length monobody, a fragment of a monobody, a peptide, or a polyamino
- the affinity reagent is directly conjugated to a detection reagent and/or purification reagent.
- the detection reagent and purification reagent are the same. In other cases, the detection reagent and purification reagent are different.
- the detection reagent and/or purification reagent is fluorescent, magnetic, or the like. In some cases, the detection reagent and/or purification reagent is a magnetic particle for column purification.
- Affinity reagents can comprise immunoaffinity reagents, utilizing the binding specificity of antibodies or fragments or derivatives thereof to positively or negatively select for a cell population of interest.
- Selection methods for cell populations can comprise an affinity agent and a column, such as magnetic activated cell sorting (MACS) with specific antibodies and microbeads.
- Selection methods for cell populations can comprise fluorescent activated cell sorting (FACS), with cell populations sorted based on staining profiles with one or more fluorescently-conjugated antibodies.
- Selection methods for cell populations can comprise physical adsorption, for example, physical adsorption of T cells to protein ligands such as lectins.
- a large number of anti-human CD-39 antibodies are commercially available and can find use for this purpose, including without limitation, antibodies sold by Amcam: Rabbit monoclonal [EPR26473-58] to CD39; Rabbit monoclonal [EPR20627] to CD39; Mouse monoclonal [AC2] to CD39; Rabbit monoclonal [EPR20461 ] to CD39; Rabbit monoclonal [EPR3678(2)] to CD39; Rabbit monoclonal [EPR26473-58] to CD39; Mouse monoclonal [IMG17B5F11] to CD39; Mouse monoclonal [A1] to CD39; APC Mouse monoclonal [TU66] to CD39; FITC Mouse monoclonal [A1] to CD39; and PE Mouse monoclonal [TU66] to CD39; antibodies sold by Invitrogen: CD39 Monoclonal Antibody (eBioAl (A1 )); CD39 Recombinant Rabbit Monoclonal Antibody (eBioA
- a population of cells comprising CAR-Tregs can be selected using magnetic activated cell sorting (MACS).
- a population of cells comprising Tregs can be selected using fluorescent activated cell sorting (FACS).
- a population of cells comprising Tregs can be selected using multiple procedures, for example, multiple MACS selections, multiple FACS selections, or a combination of MACS and FACS selections.
- the cells are first enriched by CD25 expression by CliniMACS immunomagnetic selection, followed by flow cytometric sorting for CD4 + , CD127 l0/ne9 expression.
- the resulting product is enriched for Tregs defined phenotypically as CD4 + , CD25 + , CD127 l0/ne9 and expressing the transcription activator FoxP3.
- FoxP3 detection is used only to assess the percentage of CAR-Tregs in samples drawn from the final cellular product for infusion.
- the final population is selected into CD39 positive and negative fractions.
- the cells are characterized by their expression of cell surface markers. For several of these markers, the expression is low or intermediate in level. While it is commonplace to refer to cells as “positive” or “negative” for a particular marker, actual expression levels are a quantitative trait. The number of molecules on the cell surface can vary by several logs, yet still be characterized as “positive”. Characterization of the level of staining permits subtle distinctions between cell populations.
- the staining intensity of cells can be monitored by flow cytometry, where lasers detect the quantitative levels of fluorochrome (which is proportional to the amount of cell surface antigen bound by the antibodies).
- Flow cytometry, or FACS can also be used to separate cell populations based on the intensity of antibody staining, as well as other parameters such as cell size and light scatter.
- the absolute level of staining may differ with a particular fluorochrome and antibody preparation, the data can be normalized to a control.
- each cell is recorded as a data point having a particular intensity of staining.
- These data points may be displayed according to a log scale, where the unit of measure is arbitrary staining intensity.
- the brightest cells in a bone marrow sample are designated as 4 logs more intense than the cells having the lowest level of staining.
- the “low” staining cells may fall in the 2-3rd log of staining intensity.
- An alternative control may utilize a substrate having a defined density of antigen on its surface, for example a fabricated bead or cell line, which provides the positive control for intensity.
- the sorted CAR-Treg cells may be activated in vitro for a period of time of at least about 24 hours, and not more than about 48 hours at 37°C.
- the in vitro activation can be from about 24 hours, from about 26 hours, from about 28 hours, from about 30 hours, from about 32 hours, from about 34 hours from about 36 hours, up to about 48 hours, up to about 46 hours, up to about 44 hours, up to about 42 hours, up to about 40 hours, up to about 38 hours, and may be for about 24, about 30, about 36, about 42, about 48 hours.
- the cells are suspended in medium at a concentration of from about 0.9 x 10 5 viable cells/ml from about 1 x 10 6 , up to about 2 x 10 6 ; up to about 3 x 10 6 and may be at a concentration of from about 1.1 x 10 6 to about 2 x 10 6 viable cells/ml, e.g. at about 1.1 x 10 6 ; 1 .2 x 10 6 ; 1 .3 x 10 6 ; 1 .4 x 10 6 ; 1.5 x 10 6 ; 1 .6 x 10 6 ; 1.7 x 10 6 ; 1.8 x 10 6 ; 1 .9 x 10 6 ; 2 x 10 6 .
- the medium comprises an suitable cell medium, e.g. TexMACsTM, etc., and effective dose of human serum, a T cell activating agent, e.g. TransActTM (Miltenyi); and IL-2.
- a T cell activating agent e.g. TransActTM (Miltenyi); and IL-2.
- Each of the reagents is generally GMP grade.
- Human serum may be present at a concentration of from about 5% to about 15% vol/vol, e.g. from about 6%, about 7%, about 8% about 9%, about 10% about 1 1 % about 12%, up to about 15%, up to about 14%, up to about 13%, up to about 13%, up to about 12%, and may be present at about 10% concentration.
- IL-2 is present at a concentration of from about 100 lU/ml up to about 5000 lU/ml, e.g. from about 100 IU, from about 200 IU, from about 300 IU, from about 400 IU, from about 500 IU, up to about 5000 IU, up to about 4000 IU, up to about 3000 IU, up to about 2000 IU, up to about 1000 IU, and may be present at about 500 IU.
- TransActTM may be added in accordance with the manufacturers’ guideline, e.g. diluted from about 1 :20 to about 1 :10, and may be 1 :17.5, 1 :15, 1 :12.5, etc.
- the activated Treg calls are optionally cryopreserved.
- Cryopreservation can comprise addition of a preservative agent (e.g., DMSO), and gradual cooling of cells in a controlled-rate freezer to prevent osmotic cellular injury during ice crystal formation.
- Cryopreservation can comprise commercial cryopreservation reagents and materials, for example, Cryobags and CryoStor® CS10.
- the cells are resuspended in Normosol-R, pH 7.4; with hydroxyethyl starch 30.5%; human serum albumin (HSA) 12%; and DMSO 7.5%.
- Cryopreserved cells can be stored for periods of time ranging from hours to years at low temperatures.
- Cryopreserved cells can be stored at ultralow temperatures, for example, -50 aC, -60 9 C, -70 9 C, -80 a C, -90 9 C, -100 9 C, -110 e C, -120 9 C, -130 9 C, -140 e C, -150 9 C, -160 9C, 170 9 C, -180 9 C, -190 a C, -196 e C, or less.
- Cryopreserved cells can be stored in storage devices comprising liquid nitrogen.
- the cells Post-thaw the cells are placed in a suitable medium comprising human serum and IL- 2, and may be activated a second time, in the absence of the T cell activating agent.
- the cells are suspended in medium at a concentration of from about 0.9 x 10 5 viable cells/ml from about 1 x 10 6 , up to about 2 x 10 6 ; up to about 3 x 10 6 and may be at a concentration of from about 1 .1 x 10 6 to about 2 x 10 6 viable cells/ml, e.g. at about 1 .1 x 10 6 ;
- a T cell activating agent e.g. TransActTM is added to the cells and the cell suspension returned to 37°C, 5% CO 2 for a period of from about 12 to about 24 hours, e.g. from about 12 hours, from about 14 hours, from about 16 hours, from about 18 hours, from about 20 hours, up to about 24 hours, up to about 22 hours, up to about 20 hours, up to about 18 hours, up to about 16 hours.
- a population of cells comprising CD39 + CAR-Tregs or CD39 CAR-Tregs can be administered to a subject at a dose greater than at least about 1 x 10 4 , 1 x 10 5 , 2 x 10 5 , 3 x
- a population of cells comprising CD39 + CAR-Tregs or CD39' CAR-Tregs administered to a subject can be administered at a dose of at most about 1 x 10 4 , 1 x 10 5 , 2 x 10 5 , 3 x 10 5 , 4 x 10 5 , 5 x 10 5 , 6 x 10 5 , 7 x 10 5 , 8 x 10 5 , 9 x 10 5 , 1 x 10 6 , 1 .1 x 10 6 , 1 .2 x 10 6 , 1.3 x 10 6 , 1.4 x 10 6 , 1 .5 x 10 6 , 1.6 x 10 6 , 1 .7 x 10 6 , 1 .8 x 10 6 , 1.9 x 10 6 , 2 x 10 6 , 2.1 x 10 6 , 2.2 x 10 6 , 2.3 x 10 6 , 2.4 x 10 6 , 2.5 x 10
- Tregs are defined as CD4+CD25+CD127dim, CD3+CD4+CD25+, CD3+ CD4+ CD25+ CD127dim, CD3+ CD4+ CD25+ CD127dim FOXP3+,
- a population of cells comprising CD39 + CAR-Tregs or CD39’ CAR-Tregs of the disclosure can comprise, for example, greater than at least about 50%, 51%, 52%, 53%, 54%,
- FOXP3+ cells as a percentage of total cells, nucleated cells, or CD45+ cells, or CD4+CD25+CD127dim cells as a percentage of total cells, nucleated cells, or CD45+ cells, or as a percentage of total cells, nucleated cells, or CD45+ cells.
- a population of cells comprising CD39 + CAR-Tregs or CD39’ CAR-Tregs of the disclosure can have a defined level of contaminating non-Treg cells. For example, greater than at least about 1 x 10 2 , 2 x 10 2 , 3 x 10 2 , 4 x 10 2 , 5 x 10 2 , 6 x 10 2 , 7 x 10 2 , 8 x 10 2 , 9 x 10 2 , 1 x 10 3 , 2 x 10 3 , 3 x 10 3 , 4 x 10 3 , 5 x 10 3 , 6 x 10 3 , 7 x 10 3 , 8 x 10 3 , 9 x 10 3 , 1 x 10 4 , 2 x 10 4 , 3 x 10 4 , 4 x 10 4 , 5 x 10 4 , 6 x 10 4 , 7 x 10 4 , 8 x 10 4 , 9 x 10 4 , 1 x 10 4 , 2 x
- a population of cells comprising CD39 + CAR-Tregs or CD39" CAR-Tregs of the disclosure can comprise, for example, greater than at least about 0.001 %, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008% 0.009%, 0.01 %, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1 %, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1 %, 1 .1 %, 1 .2%, 1 .3%, 1 .4%, 1 .5%, 1 .6%, 1 .7%, 1 .8%, 1 .9%, 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, 3.1 %, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%,
- a population of cells comprising CD39 + CAR-Tregs or CD39" CAR-Tregs of the disclosure comprises at most about 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008% 0.009%, 0.01 %, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1 %, 1.1 %, 1 .2%, 1 .3%, 1 .4%, 1 .5%, 1 .6%, 1 .7%, 1 .8%, 1 .9%, 2%, 2.1 %, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%,
- CAR Treg cells are useful in a variety of conditions, including, for example, treatment of cancer, in association with hematopoietic stem cell transplantation (HCT), for example to reduce graft v host disease, to reduce allograft rejection, and the like.
- HCT hematopoietic stem cell transplantation
- a condition to be treated is an autoimmune disease, allergic disease, or inflammatory disease.
- a population of cells comprising CD39 selected CAR-Tregs can be administered to an HCT recipient subject, and the population of CD39 selected CAR-Tregs can serve to reduce or prevent GVHD in the HCT recipient subject.
- GVHD graft-versus-host disease
- aGVHD acute GVHD
- cGVHD chronic GVHD
- aGVHD typically occurs in the first 3 months after transplantation.
- aGVHD can be life-threatening and can involve, for example, the skin, the intestines, and/or the liver.
- cGVHD typically occurs after the first 3 months following transplant.
- cGVHD is a major source of late treatment-related complications, and can be life-threatening.
- cGVHD can lead to the development of fibrosis, which can result in functional disability.
- aGVHD acute graft versus host disease
- cGVHD chronic GVHD
- the incidence of aGVHD following allogeneic HCT from an HLA-matched sibling donor (MSD) is 20 to 60%, despite the use of various immunosuppressive agents such as tacrolimus, cyclosporine, methotrexate, mycophenolate, anti-thymocyte globulin and corticosteroids.
- various immunosuppressive agents such as tacrolimus, cyclosporine, methotrexate, mycophenolate, anti-thymocyte globulin and corticosteroids.
- Approximately one-third of patients who undergo allogeneic HCT using a MSD and a T cell replete graft will develop chronic GVHD.
- GVHD severity can be graded, for example, using the Glucksberg grade (l-IV) or the International Bone Marrow Transplant Registry (IBMTR) grading system (A-D).
- the severity of acute GVHD is determined by an assessment of the degree of involvement of the skin, liver, and gastrointestinal tract. The stages of individual organ involvement are combined with (Glucksberg) or without (IBMTR) the patient’s performance status to produce an overall grade, which can have prognostic significance. Grading is important in terms of assessing the response to prophylaxis or treatment, impact upon survival, and association with graft-versus- leukemia effect.
- Grade l(A) GVHD is characterized as mild disease, grade ll(B) GVHD as moderate, grade lll(C) as severe, and grade IV(D) life-threatening.
- the IBMTR grading system defines the severity of acute GVHD as follows: Grade A: stage 1 skin involvement alone (maculopapular rash over ⁇ 25 percent of the body) with no liver or gastrointestinal involvement; Grade B: stage 2 skin involvement, stage 1 to 2 gut or liver involvement; Grade C: stage 3 involvement of any organ system (generalized erythroderma; bilirubin 6.1 to 15.0 mg/dL; diarrhea 1500 to 2000 mL/day); Grade D: stage 4 involvement of any organ system (generalized erythroderma with bullous formation; bilirubin >15 mg/dL; diarrhea >2000 mL/day OR pain OR ileus). Patients with moderate to severe GVHD have a significantly higher mortality rate compared with those with milder disease, for example, estimated five year survival for patients with grade III (C) aGVHD
- GVHD may require immunosuppressive therapy (for example, high dose corticosteroids, prolonged administration of immunosuppressants) or cytotoxic mediations, all of which are associated with toxicity.
- immunosuppressive therapies can fail to effectively treat GVHD, or can result in increased susceptibility to infection, or blunted anti-tumor immunity.
- administration of the CD39 selected CAR-Treg cells, particularly CD39 + CAR-Treg cells of the disclosure disclosed herein prevent or reduce GVHD in an HCT recipient subject.
- the methods disclosed herein can prevent any manifestation of GVHD in a subject receiving HCT.
- the CAR of such cells is targeted to a transplantation alloantigen, e.g. an HLA Class I or HLA Class II antigen.
- the methods disclosed herein can prevent, for example, any GVHD of stage 1 or above, any GVHD of stage 2 or above, any GVHD of stage 3 or above, or any GVHD of stage 4 in subjects receiving HCT.
- Type 1 diabetes is an autoimmune disorder characterized by insulin deficiency due to the destruction of pancreatic p cells.
- Studies have shown reduced immune suppressive functionality of Tregs in patients with T1 D. This observation and the success of Treg transplantation in maintaining immunologic tolerance has led to the application of Treg infusion in T1 D patients to rescue remaining cells. Infusion of expanded antigen-specific Tregs showed promising results in animal models in blocking and reversing diabetes.
- administration of the CD39 selected CAR-Treg cells, particularly CD39 + CAR-Treg cells of the disclosure disclosed herein prevent or reduce T1 D in a recipient.
- the methods disclosed herein can prevent any manifestation of T1 D in a subject.
- the CAR of such cells is targeted to a pancreatic antigen, e.g. glutamic acid decarboxylase (GAD), insulin, HPi2, immunodominant GAD65 beta-cell epitopes, etc.
- GAD glutamic acid decarboxylase
- the autoimmune disease, allergic disease, or inflammatory disease is transplant rejection.
- the transplant rejection occurs in response to transplanted blood, bone marrow, bone, skin, heart, kidney, lung, muscle, heart or liver.
- the transplant rejection is hyperacute rejection.
- the transplant rejection is acute rejection.
- the transplant rejection is chronic rejection.
- the transplant is allogeneic islet transplantation.
- the CD39 selected CAR-Tregs of the disclosure comprise a CAR that targets a human leukocyte antigen.
- the HLA targeted by the CAR is the same HLA allele as a donor.
- the donor is HLA-A*2:0l and the CAR- Treg targets HLA- A* 2:0.1
- the human leukocyte antigen targeted by the CAR is the same HLA allele as a recipient. All alleles of HLA-A, HLA-B and HLA-C are envisaged as within the scope of the disclosure.
- the method increases CD45+ cell engraftment, increases overall survival, decreases serum inflammatory cytokines or a combination thereof.
- the method decreases spleen inflammation, liver inflammation, lung inflammation, inflammation of the central nervous system (CNS), inflammation of the skin, inflammation of the pancreas, inflammation of the kidney, inflammation of the pleural cavity, inflammation of the gastrointestinal tract, inflammation of the genitourinary tract, or inflammation of the pelvis.
- the disclosure provides a method for reducing transplant rejection in a patient transplanted with hematopoietic stem cells, bone marrow cells, or a solid organ, comprising providing administering the CD39 selected CAR- Tregs to the patient.
- the method prevents allograft rejection, improving upon concepts described in Noyan et al. (2017) Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor. Am. J. Transplantation 2017; 17: 917-930.
- PBMC peripheral blood mononuclear cell
- Natural regulatory T cells (nTregs; CD3+ CD4+ CD8-CD25highCD127low) and autologous CD4+ T cells required for suppression assays were isolated by enrichment from PBMCs using EasySep Human CD4+CD127lowCD25+ Regulatory T Cell Isolation Kit (StemCell Technologies) according to the manufacturer’s instructions.
- the isolated Treg then were purified with fluorescence-activated cell sorting using the following gates: lymphocytes, single cells, live (aqua-), whole Treg CD3+CD4+CD8- CD25hiCD127-, CD39+ Treg CD3+CD4+CD8-CD25hiCD127-CD39+ and CD39- Treg CD3+CD4+CD8-CD25hiCD127-CD39-
- the monoclonal antibody combinations were as listed on Table 1.
- the FACS-based cell sorting was performed at Stanford Shared FACS Facility using a FACSAriaTM II Cell Sorter (Beckton Dickinson) and had a purity of >99.0%.
- Sorted populations were expanded in X-VIVOTM 15 Chemically Defined Medium, with gentamicin and phenol red (Lonza) supplemented with 10% heat inactivated Human male AB serum (Sigma-Aldrich) and 10% L-glutamine(HyCloneTM), 10% Sodium Pyruvate(Gibco) and 10% non-essential amino acids(NEAA)(Fisher) in the presence of recombinant human IL-2 (rlL-2, PeproTech) (100 lU/ml for Teff; 500 lU/ml for Tregs), expanded by using Dynabeads® Human T-Activator CD3/CD28(Gibco) according to the manufacturer’s instructions.
- Tregs have been cultured for 12 consecutive days, checked every 6 days for purity by FACS analysis (CD4+FoxP3+ cells constantly > 90%), washed, and then transfected. To evaluate the purity of Tregs isolated by this cell-sorting scheme, they were stained with anti-FoxP3 (Clone 206D, BioLegend) in FoxP3 staining buffer (eBioscience). Flow cytometry data were acquired on an LSRII or FACS Caliber (Becton Dickinson); FACS Diva software (BD) and FlowJo version v10 software (Treestar) were used for analysis.
- rhlL-2 recombinant human IL-2
- Cells were transfected with 2 pg of HLA-A2 CAR mRNA or 2 pg of 1 x9Q mRNA. After electroporation, cells were plated in a 6-well plate in 2 ml of CM RPMI 1640 with 500 IU rhlL-2/ml without antibiotics. The CAR construct expression efficacy was checked using Flag or Tetra HLA-A2. Cells were then used for functional assay described below.
- [001 16] Glucose-induced insulin-secretion test. Islets after coculture with CAR-Treg for 48 hours were preincubated in a modified Krebs-Ringer Bicarbonate buffer (KRBB) containing 1 15 mmol/l NaCI, 5 mmol/l KCI, 24 mmol/l NaHCOs, 2.2 mmol/l CaCL, 1 mmol/l MgCL, 20 mmol/l HEPES, 2 g/l human serum albumin (Cealb, Sanquin, The Netherlands), pH 7.4 for 2 hours.
- KRBB modified Krebs-Ringer Bicarbonate buffer
- islets were cultured in Krebs-Ringer bicarbonate buffer (KRBB) with 1 % bovine serum albumin (BSA) and with 2.8 mM glucose for 1 hour. Then islets were cultured in KRBB containing 2.8 mM or 16.7 mM glucose for additional 2 hours at 37°C. Afterwards, the supernatants were collected. Insulin concentrations were determined in the supernatants using Human Insulin ELISA Kit(Sigma-Aldrich)
- FDA fluorescein diacetate
- PI propidium iodide
- islets were dispersed with Accumax - Cell Aggregate Dissociation Medium (InvitrogenTM) and cocultured with CAR-Treg in 96-well plates at a density of 1 *10 5 dispersed islet cells for 48 hours. Then cells were collected and stained with FITC Annexin V Apoptosis Detection Kit with 7-AAD(BioLegend) according to the manufacturer’s instructions. Data were collected using a FACS Aria II analyzer and analyzed using Flowjo v10 software.
- Monocyte Viability Assessment Using flow Monocytes were isolated by enrichment from PBMCs using EasySep Human Monocyte Isolation Kit (StemCell Technologies) according to the manufacturer’s instructions. The isolated monocyte were then purified with fluorescence-activated cell sorting using the following gates: lymphocytes, single cells, live (aqua-), CD14+HLA-DR+CD11 b+CD3-CD56-CD19- The monoclonal antibody combinations were as listed on Table 1. Monocyte were cocultured with CAR-Treg in 48-well plates at a density of 1 x10 6 /ml for 48 hours.
- the coverslips were washed once gently with PBS, pH 7.2, avoiding removal of dying cells.
- the cells were fixed in room-temperature 4% paraformaldehyde (PFA) for one hours. And samples then were permeabilized with 0.1 % Triton X-100, 0.1 % sodium citrate, for 2 minutes at room temperature.
- 50 pl of TUNEL reaction solution In Situ Cell Death Detection Kit, Fluorescein, Roche; Enzyme solution+Label solution
- Nuclei were stained with DAPI (100 ng/mL; MilliporeSigma). Negative controls for TUNEL staining included only 50ul label solution.
- Table 1 Antibodies used for flow cytometry.
- Target Clone Fluorochrome Vendor RRID Target Clone Fluorochrome Vendor RRID
- HLA-A2 BB7.2 PE BioLegend AB_1877227
- HLA-A2 BB7.2 APC BioLegend AB_2561567
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Molecular Biology (AREA)
Abstract
Compositions and methods are provided herein relating to Treg cells modified by introduction of a chimeric antigen receptor (CAR), referred to herein as CAR-Treg cells. Populations of CAR-Treg cells are bimodal with respect to expression of the surface marker CD39; where the cytotoxic potential of the cell population segregates with respect to such CD39 expression. Selection for a CD39+ CAR-Treg population provides for a population with significantly reduced cytotoxic risk toward the cell population targeted by the CAR. In contrast, selection for a CD39+ CAR-Treg population provides for a population with enhanced cytotoxicity toward the cell population targeted by the CAR deleting antigen.
Description
CD39 SELECTION FOR CYTOTOXICITY OF GENETICALLY ENGINEERED T REGULATORY CELLS
CROSS REFERENCE TO OTHER APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63/425,109, filed November 14, 2022, the contents of which are hereby incorporated by reference in its entirety.
GOVERNMENT RIGHTS
[0002] This invention was made with Government support under contracts DK132549 awarded by the National Institutes of Health. The Government has certain rights in the invention.
BACKGROUND
[0003] Regulatory T cells (Tregs) are a specialized subpopulation of T cells that act to suppress immune response, thereby maintaining homeostasis and self-tolerance. It has been shown that Tregs are able to inhibit T cell proliferation and cytokine production and play a critical role in preventing autoimmunity. Different subsets with various functions of Treg cells exist. Tregs can be usually identified by flow cytometry. The most specific marker for these cells is FoxP3, which is localized intra-cellularly. Dysregulation in Treg cell frequency or functions may lead to the development of autoimmune disease. Therapeutic Treg modulation is being developed to treat certain immune disorders, for example to prevent graft v host disease, or allograft rejection.
[0004] Promising results of initial studies using Treg as a clinical intervention have increased interest in this type of the cellular therapy. As such, methods of isolation and expansion of Tregs have been studied and optimized. Further, preclinical studies have shown antigenspecific Tregs may be more efficient due to their homing ability towards the cognate antigen. Antigen specificity can be conferred to regulatory T cells by transducing them with recombinant TCR. TCR-engineered T cells recognize peptides from both intracellular and surface derived proteins. Moreover, TCR-T cells have high affinity to cognate major histocompatibility complex (MHC)-peptide and induce a potent immune synapse formation. However, TCR-engineered Tregs are MHC dependent. Chimeric antigen receptor (CAR) technology offers a non-MHC- dependent approach. Such CAR-Treg cells utilize an extracellular antigen recognition domain from a single-chain variable fragment (scFv) of an antibody combined with an intracellular signaling domain. Many other creative receptor-targeted engineered fusion proteins are also being explored to direct and activate T regulatory cells to specific tissue or secreted targets. This combination allows for the construct to activate a T-cell response without interacting with the antigen in the context of MHC.
[0005] T regulatory cells can also be present in T cell cultures for CAR T cells expanded and transduced for cancer targeting such as targeting B cells through CD19. T regulatory cells in bulk are less effective in general in cytotoxic killing of target cancer and may affect the success of CAR T therapy by interfering with conventional T cells mediating anti-cancer responses. Subsets that do not mediate cytotoxic killing but are immunoregulatory may contribute exceptionally to reducing the efficacy of CAR T therapy. Likewise, subsets of T regulatory cells that are cytotoxic may be preferred as CAR T therapeutics because they are likely to function when CD8 or other T cell subsets become exhausted, anergic or otherwise hyper-activated and lose efficacy.
SUMMARY
[0006] Compositions and methods are provided herein relating to Treg cells modified by introduction of a chimeric antigen receptor (CAR), referred to herein as CAR-Treg cells. The CAR selectively binds to an antigen present on a target cell population. It is shown herein that populations of CAR-Treg cells are bimodal with respect to expression of the surface marker CD39; and that the cytotoxic potential of the cell population segregates with respect to such CD39 expression. Selection for a CD39+ CAR-Treg population provides for a population with significantly reduced cytotoxic risk toward the cell population targeted by the CAR, and may improve immunoregulatory function. These CD39+ CAR-Treg cell populations are useful in the treatment of conditions where it is desirable for the Treg cells to enhance immune tolerance, e.g. in the treatment of autoimmune disease, to reduce graft v host disease, to provide tolerance in transplantation, to promote wound healing or tissue regeneration and the like. In contrast, selection for a CD39' CAR-Treg population provides for a population with enhanced cytotoxicity toward the cell population targeted by the CAR deleting antigen, which can find use in depletion of targeted populations, e.g. in cancer, depletion of undesirable antigen- presenting cells such as those present in transplantation rejection, autoimmune or inflammatory diseases, and the like.
[0007] In an embodiment, a composition is provided of CAR-Treg cells with reduced cytotoxic activity against the CAR-targeted cell population, relative to the unselected CAR-Treg population from which it is derived. The CAR-Treg cells are characterized by CD39 expression, i.e. the cells are CD39+. The reduction in cytotoxicity may be measured, e.g. by an assay for apoptosis of target cells, where the reduction is at least 25%, at least 50%, at least 75% decrease, and may be a two-fold decrease or greater decrease in cytotoxicity relative to an unselected population. The cell population may be provided as a composition suitable for therapeutic administration. A therapeutic composition may comprise a therapeutically effective dose of CD39+ CAR-Treg cells, in a physiologically acceptable excipient.
[0008] In an embodiment, a composition is provided of CAR-Treg cells with enhanced cytotoxic activity against the CAR-targeted cell population, relative to the unselected CAR- Treg population from which it is derived. The CAR-Treg cells are characterized low levels or the absence of CD39 expression. The enhancement in cytotoxicity may be measured, e.g. by an assay for apoptosis of target cells, where the enhancement is at least 25%, at least 50%, at least 75% increase, and may be a two-fold increase or greater in cytotoxicity, relative to unselected cells. The cell population may be provided as a composition suitable for therapeutic administration. A therapeutic composition may comprise a therapeutically effective dose of CD39" CAR-Treg cells, in a physiologically acceptable excipient. CD39- CAR Treg cells can regain some CD39+ expression with ex vivo cell culture expansion but retain the ability to have increased cytotoxicity.
[0009] In some embodiments, a method of treating an individual with a therapeutically effective dose of CAR-Treg cells or other genetically modified Treg cells, e.g. T cell receptor transduced cells, is provided, comprising administering to an individual in need thereof an effective dose of a population of genetically modified Treg cells, e.g. CAR-Treg cells that have been selected based on CD39 expression. Conditions where the cells are used may include, for example, GVHD, type 1 diabetes, autoimmunity, wound healing, tissue regeneration and transplantation tolerance.
[0010] In an embodiment, methods of treating or inhibiting autoimmune disease, allergic disease, or inflammatory disease in a patient in need thereof are provided, comprising administering an effective dose of a CD39 selected CAR-Treg cell population to an individual in need there.
[001 1] In an embodiment, methods of reducing transplant rejection in a patient transplanted with hematopoietic stem cells, bone marrow cells, or a solid organ are provided, comprising administering an effective dose of a CD39 selected CAR-Treg cell population to an individual in need there.
[0012] In some embodiments, a method is provided for the in vitro culture and genetic modification of T cells to generate a population of CAR-Treg cells with reduced cytotoxic activity against the CAR-targeted cell population. An initial T cell population is isolated from a donor, which may be allogeneic or autologous relative to the recipient. The T cells may be a population comprising CD4+ T cells, optionally a population selected for Treg cells. In populations that are not selected Tregs, the cells can be engineered by transducing with CAR constructs and FoxP3 coding sequences. Treg populations are transduced with CAR constructs but do not require FoxP3. The population is sorted based on expression of CD39, e.g. by affinity selection such as flow cytometry, MACs, and the like. Selection may be performed or after transductions, usually after. The population of CD39 selected, CAR-Treg cells may be expanded in culture, activated, cryopreserved, and the like.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] The invention is best understood from the following detailed description when read in conjunction with the accompanying drawings. It is emphasized that, according to common practice, the various features of the drawings are not to-scale. On the contrary, the dimensions of the various features are arbitrarily expanded or reduced for clarity. Included in the drawings are the following figures.
[0014] FIG. 1 Co-culture of human CAR Treg targeting human islets in cell culture. Cytotoxic killing of islets can occur as identified by flow cytometric assessment of annexin V and 7AAD in human islet beta cells specifically. Unselected Tregs from HLA-A2 negative donors identified as CD4+CD25+CD17lo were culture expanded and transduced with CAR construct with A2-specific scFv and CD3zeta and CD28 internal stimulatory domain. The HLA-A2 specific CAR Treg specifically caused a decrease in the number of normal healthy islet beta cells that did not express Annexin V or incorporate 7 AAD (normalized to islets in cell culture alone as), as compared to untransduced Treg (mock), or Treg with irrelevant scFv binding domains (1 X9Q that binds FITC) and FRB which binds a myeloid-specific cell surface marker.
[0015] FIG. 2. Co culture of expanded allogeneic human Tregulatory cells as a group or as CD39+ versus CD39- with human islets in vivo does not result in any changes in Treg cytotoxic killing of islets, so the discovery that CD39+ and CD39= CAR Treg behave differently is not anticipated.
[0016] FIG. 3. When looking at ex vivo culture expanded total Treg as a whole, those CAR Treg with the lowest CD39 expression had the highest cytotoxic activity as measured by islet cell death.
[0017] FIG. 4. CD39+ Treg show distinct features cmTreg: the cells of this weakly proliferating population circulate between secondary lymphoid organs and express anti-apoptotic factors Bcl-2 and Mcl-1 at a high level. Not prone to apoptosis, great potential to have a longer in vivo survival time after injection.
[0018] FIG. 5. CD39+ Treg show more stable and higher FOXP3 expression and more phenotypic stability in cell culture expansion compared to CD39-
[0019] FIG. 6. CD39+ expanded Tregs have statistically lower expression of granzyme when compared to bulk/whole Treg versus CD39- Treg. The difference in the ratio of central memory to effector memory in these cells becomes more pronounced after expansion.
[0020] FIG. 7. CD39 Treg have higher LAG3 expression, suggesting a more suppressive phenotype.
[0021] FIG. 8. |3lox5 cells were derived from purified adult pancreatic beta cells and microscopic evaluation confirms HLA-A2 CAR Treg mediate cytotoxic killing of tissue targets.
[0022] FIG. 9. Primary pancreatic islet cells were derived from purified adult pancreatic beta cells and microscopic evaluation confirms HLA-A2 CAR Treg mediate cytotoxic killing of tissue targets.
[0023] FIG. 10. A2 CAR CD39 negative T reg cells directly induce islet cytolysis.
[0024] FIG. 1 1. A2 CAR Treg that are CD39+ preserve glucose-stimulated insulin secretion in target organs, versus CD39- cells that had reduced islet functionality.
DETAILED DESCRIPTION
[0025] Before the present methods and compositions are described, it is to be understood that this invention is not limited to particular method or composition described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0026] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
[0027] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. It is understood that the present disclosure supercedes any disclosure of an incorporated publication to the extent there is a contradiction.
[0028] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and reference to "the peptide" includes reference to one or more peptides and equivalents thereof, e.g. polypeptides, known to those skilled in the art, and so forth.
[0029] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
[0030] As used herein, the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length. In one embodiment, the term “about” or “approximately” refers a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length ± 15%, ± 10%, ± 9%, ± 8%, ± 7%, ± 6%, ± 5%, ± 4%, ± 3%, ± 2%, or ± 1 % about a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
[0031] As used herein, the term “isolated” means material that is substantially or essentially free from components that normally accompany it in its native state. In particular embodiments, the term “obtained” or “derived” is used synonymously with isolated.
[0032] The terms “subject,” “patient” and “individual” are used interchangeably herein to refer to a vertebrate, preferably a mammal, more preferably a human. Tissues, cells, and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed. A “subject,” “patient” or “individual” as used herein, includes any animal that exhibits pain that can be treated with the vectors, compositions, and methods contemplated herein. Suitable subjects (e.g., patients) include laboratory animals (such as mouse, rat, rabbit, or guinea pig), farm animals, and domestic animals or pets (such as a cat or dog). Non-human primates and, preferably, human patients, are included.
[0033] As used herein “treatment” or “treating,” includes any beneficial or desirable effect, and may include even minimal improvement in symptoms. “Treatment” does not necessarily indicate complete eradication or cure of the disease or condition, or associated symptoms thereof.
[0034] As used herein, “prevent,” and similar words such as “prevented,” “preventing” etc., indicate an approach for preventing, inhibiting, or reducing the likelihood of a symptom of disease. It also refers to delaying the onset or recurrence of a disease or condition or delaying the occurrence or recurrence of the symptoms of a disease. As used herein, “prevention” and similar words also includes reducing the intensity, effect, symptoms and/or burden of disease prior to onset or recurrence.
[0035] As used herein, the term “amount” refers to “an amount effective” or “an effective amount” is the dose of a cell population that achieves a beneficial or desired prophylactic or therapeutic result, including clinical results.
[0036] A “therapeutically effective amount” of a cell population may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the virus or cell to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the cell are outweighed by the therapeutically beneficial effects. The term “therapeutically effective amount” includes an amount that is effective to “treat” a subject (e.g., a patient).
[0037] An “increased” or “enhanced” amount of a physiological response, e.g. cytotoxicity against a target cell, is typically a “statistically significant” amount, and may include an increase that is 1.1 , 1 .2, 1 .5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1 , e.g., 1.5, 1.6, 1 .7. 1 .8, etc.) the level of activity in an untreated cell.
[0038] A “decrease” or “reduced” amount of a physiological response, e.g. cytotoxicity against a target cell, is typically a “statistically significant” amount, and may include an decrease that is 1.1 , 1 .2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1 , e.g., 1 .5, 1 .6, 1 .7. 1 .8, etc.) the level of activity in an untreated cell.
[0039] By “maintain,” or “preserve,” or “maintenance,” or “no change,” or “no substantial change,” or “no substantial decrease” refers generally to a physiological response that is comparable to a response caused by either vehicle, or a control molecule/cell composition. A comparable response is one that is not significantly different or measurable different from the reference response.
[0040] The term “exogenous” is used herein to refer to any molecule, including nucleic acids, protein or peptides, small molecular compounds, and the like that originate from outside the organism. In contrast, the term “endogenous” refers to any molecule that originates from inside the organism (i.e., naturally produced by the organism).
[0041] Regulatory T cells (“Tregs”) are a specialized subpopulation of T cells that can suppress activation of the immune system and thereby maintain immune tolerance. Tregs are share the phenotype of being CD4+ CD25+ FOXP3+. There are various types of Tregs, for example, TCRa|3+CD4+ regulatory T cells, which include natural regulatory T cells (nTregs) and induced regulatory T cells (iTregs). nTregs are T cells produced in the thymus and delivered to the periphery as a long-lived lineage of self-antigen-specific lymphocytes. iTregs are recruited from circulating lymphocytes and acquire regulatory properties under particular conditions of stimulation in the periphery. nTregs and iTregs are CD4+CD25+; both can inhibit proliferation of CD4+CD25- T cells in a dose-dependent manner, and both are anergic and do not proliferate upon TOR stimulation. Tregs can be identified or selected based on various marker expression profiles. Non-limiting examples of marker expression profiles that can be
used to select Tregs include (1 ) CD4+CD25+CD127dim, (2) CD4+FOXP3+, (3) CD3+CD4+CD25+, (5) CD3+ CD4+ CD25+ CD127dim, (6) CD3+ CD4+ CD25+ CD127dim F0XP3+, (7) CD3+FOXP3+, (8) CD3+CD4+FOXP3+, (9) CD3+ CD4+CD25+FOXP3+, (10) CD3+CD25+FOXP3+, (11 ) CD3+CD25+CD127dim, (12) CD4+CD25+, (13)
CD4+CD25+CD127dimFOXP3+, (14) FOXP3+, CD4+FOXP3+, (15) CD4+CD25+FOXP3+, (16) CD25+FOXP3+, or (17) CD25+ CD127dim. In some embodiments, the Treg cells are CD4+CD25+CD127loFoxP3+ Treg. Selection based on certain expression profiles can be achieved based on extracellular markers and without requiring cell permeabilization, for example, selection based on CD4+CD25+CD12710 phenotype.
[0042] In some embodiments a T cell, e.g. a CD4+ T cell, is engineered to express FoxP3 to achieve a Treg phenotype. Foxp3 plays a crucial role in development and function of Treg cells. Constructs and methods from expressing Foxp3 in T cells are described in, for example, WO 2007/065957, which is incorporated herein in its entirety. In some embodiments the Foxp3 is wild-type (WT) Foxp3. Exemplary wild type human Foxp3 sequences are described in NP_054728.2, the contents of which are incorporated herein by reference.
[0043] In some embodiments, the Foxp3 is a minimal Foxp3. A “minimal Foxp3” is engineered to mimic N-terminally, C-terminally, or N-and C-terminally cleaved Foxp3 forms, see for example WO2019241549A1 , herein specifically incorporated by reference. A minimal FOXP3 may be truncated to start at residue 52 relative to the wild-type protein, and to end at residue 413 (relative to Genbank NP_054728.2). Minimal Foxp3 is, in some contexts, more active than wild-type (WT) Foxp3. In some embodiments, the minimal Foxp3 comprises a Foxp3 polypeptide that has been N-terminally truncated, C-terminally truncated, or N- and C- terminally truncated. In some embodiments, the Foxp3 is constitutively active.
[0044] In some embodiments, a polynucleotide encoding the CAR and the polynucleotide encoding the Foxp3 are configured for translation as a fusion protein comprising the CAR and the Foxp3. The CAR polynucleotide may be 5’ to the Foxp3 polynucleotide, in which case the CAR is expressed as a N-terminal fusion to the Foxp3, or vice-versa. In an embodiment, the CAR is N-terminal to the Foxp3 in the fusion protein. In an embodiment, the fusion protein comprises a cleavage site between the CAR and the Foxp3. In an embodiment, the cleavage site is a 2 A peptide.
[0045] The Treg T-cell is modified to surface express a chimeric antigen receptor (a CAR- Treg cell). As used herein, the terms “chimeric antigen receptor T-cell” and “CAR-Treg cell” are used interchangeably to refer to a T-cell that has been recombinantly modified to express a CAR. As used herein, the terms “chimeric antigen receptor” and “CAR” are used interchangeably to refer to a polyprotein comprising multiple functional domains arranged from amino to carboxy terminus in the sequence: (a) an antigen binding domain (ABD), (b) a
transmembrane domain (TD); (c) one or more cytoplasmic signaling domains (CSDs) wherein the foregoing domains (a) - (c) may optionally be linked by one or more spacer domains. The CAR may also further comprise a signal peptide sequence which is conventionally removed during post-translational processing and presentation of the CAR on the cell surface. CARs useful in the practice of the present invention are prepared in accordance with principles well known in the art.
[0046] Engineering cells to express CAR constructs is commonly accomplished through viral vector systems such as lentivirus, Gamma-retroviral, and adeno-associated viral (AAV) vectors. Additionally, viral-free systems such as the Sleeping Beauty (SB), or piggyBac transposon have been used to integrate CAR encoding DNA with favorable integration into the target genome. Furthermore, Clustered regularly interspaced short palindromic repeats (CRISPR)- CRISPR associated protein 9 (Cas9) gene-editing technology, which allows for the insertion of DNA at specific locations directed by RNA, has also been used to engineer CAR T cells. CRISPR-engineered CAR T cells, which express CAR from an endogenous TCR locus remain active for longer periods than their virus-transduced counterparts.
[0047] As used herein, the term antigen binding domain (ABD) refers to a polypeptide that specifically binds to an antigen expressed on the surface of a target cell. The ABD may be any polypeptide that specifically binds to one or more antigens expressed on the surface of a target cell.
[0048] In one embodiment, the ABD is a single chain Fv (ScFv). An ScFv is a polypeptide comprised of the variable regions of the immunoglobulin heavy and light chain of an antibody covalently connected by a peptide linker (Bird, et al. (1988) Science 242:423-426; Huston, et al. (1988) PNAS(USA) 85:5879-5883; S-z Hu, et al. (1996) Cancer Research, 56, 3055-3061 . The generation of ScFvs based on monoclonal antibody sequences is well known in the art. See, e.g. The Protein Protocols Handbook, John M. Walker, Ed. (2002) Humana Press Section 150 “Bacterial Expression, Purification and Characterization of Single-Chain Antibodies” Kipriyanov, S. Antibodies used in the preparation of scFvs may be optimized to select for those molecules which possess particular desirable characteristics (e.g. enhanced affinity) through techniques well known in the art such as phage display and directed evolution. In some embodiments, the ABD comprises an anti-CD19 scFv, an anti-PSA scFv, an anti- HER2 scFv, an anti-CEA scFv, an anti-EGFR scFv, an anti-EGFRvlll scFv, an anti-NY-ESO- 1 scFv, an anti-MAGE scFv, an anti-5T4 scFv, or an anti-Wnt1 scFv. In another embodiment, the ABD is a single domain antibody obtained through immunization of a camel or llama with a target cell derived antigen, in particular a tumor antigen. See, e.g. Muyldermans, S. (2001 ) Reviews in Molecular Biotechnology 74: 277-302. Alternatively, the ABD may be generated wholly synthetically through the generation of peptide libraries and isolating compounds having the desired target cell antigen binding properties in substantial accordance with the
teachings or Wigler, et al. United States Patent No. 6303313 B1 issued November 12, 1999; Knappik, et al., United States Patent No 6,696,248 B1 issued February 24, 2004, Binz, et al. (2005) Nature Biotechnology 23:1257-1268, and Bradbury, et al. (2011 ) Nature Biotechnology 29:245-254.
[0049] In some embodiments, the CARs of the present disclosure comprise a target-specific binding element otherwise referred to as an antigen binding moiety. The choice of moiety depends upon the type and number of ligands that define the surface of a target cell. For example, the antigen binding domain may be chosen to recognize a ligand that acts as a cell surface marker on target cells associated with a particular disease state. Thus, examples of cell surface markers that may act as ligands for the antigen moiety domain in the CAR of the invention include those associated with autoimmune disease, transplant rejection, and the like.
[0050] In some embodiments, the CAR targets specific alleles of components of the Major Histocompatibility Complex (MHC) through the extracellular domain. In some embodiments, the resulting CAR-Treg cells downregulate or suppress the immune response to alloantigens.
[0051] As used herein, “an alloantigen” refers to a genetically determined antigen present in some but not all subjects of a species and which is capable of inducing the production of an alloantibody by subjects which lack it. Exemplary alloantigens that can lead to transplant rejection include, but are not limited to, ABO blood group and Rh blood group, MHC class I or MHC class II complexes, where allele mismatches in MHC I or MHC II are significant risk factors for transplant rejection or graft-versus-host disease.
[0052] In some embodiments, the CAR targets specific alleles of components of the Major Histocompatibility Complex (MHC) e.g., HLA class 1 alleles HLA-A1 , HLA-A2, HLA-A1 1 , HLA- B44, HLA-B27, HLA-C07 and HLA-C04. In some embodiments, the MHC is MHC class I or MHC class II. In some embodiments, the CAR targets a human leukocyte antigen, e.g. an allele of human leukocyte antigen A (HLA-A, major histocompatibility complex, class I, A), human leukocyte antigen B (HLA-B, major histocompatibility complex, class I, B) or human leukocyte antigen C (HLA-C, major histocompatibility complex, class I, C).
[0053] In some embodiments, the CAR targets an allele of HLA-A. There are about 2,900 known variants of HLA-A, all of which are envisaged as within the scope of the disclosure. In some embodiments, the HLA-A allele is an HLA-A 1 , HLA-A2, HLA -Al I, HLA-A24, HLA-A26, HLA-A30, HLA-A31 , HLA-A34, HLA-A36, HLA-A66, HLA-A68 or HLA-A69 allele. In some embodiments, the HLA-A allele is an HLA- A2 allele. Exemplary HLA-A2 alleles include, but are not limited to, HLA-A*2:0l, an HLA- A*2:02, HLA-A* 2: 03, HLA-A*2:05, HLA-A*2:06, HLA- A*2:07 or HLA-A*2:0l I . In some embodiments, the extracellular domain of the CAR targets HLA-A*2:0l, an HLA-A* 2: 02, HLA-A* 2: 03, HLA-A*2:05, HLA-A*2:06, HLA-A*2:07 or HLA- A*2:0l I . In some embodiments, the extracellular domain of the CAR targets HLA-A*02:01.
[0054] In some embodiments, the CAR targets an allele of HLA-B. There are about 3,600 known variants of HLA-B, all of which are envisaged as within the scope of the disclosure. In some embodiments, the CAR targets an allele of HLA-C. There are about 2,400 known variants of HLA-B, all of which are envisaged as within the scope of the disclosure. In some embodiments, CAR targets an allele of human leukocyte antigen A (HLA-A, major histocompatibility complex, class I, A), human leukocyte antigen B (HLA-B, major histocompatibility complex, class I, B).
[0055] The ABD may have affinity for more than one target antigen. For example, an ABD of the present invention may comprise chimeric bispecific binding members, i.e. have capable of providing for specific binding to a first target cell expressed antigen and a second target cell expressed antigen. Non-limiting examples of chimeric bispecific binding members include bispecific antibodies, bispecific conjugated monoclonal antibodies (mab)2, bispecific antibody fragments (e.g., F(ab)2, bispecific scFv, bispecific diabodies, single chain bispecific diabodies, etc.), bispecific T cell engagers (BiTE), bispecific conjugated single domain antibodies, micabodies and mutants thereof, and the like. Non-limiting examples of chimeric bispecific binding members also include those chimeric bispecific agents described in Kontermann (2012) MAbs. 4(2): 182-197; Stamova et al. (2012) Antibodies, 1 (2), 172-198; Farhadfar et al. (2016) Leuk Res. 49:13-21 ; Benjamin et al. Ther Adv Hematol. (2016) 7(3):142-56; Kiefer et al. Immunol Rev. (2016) 270(1 ):178-92; Fan et al. (2015) J Hematol Oncol. 8:130; May et al. (2016) Am J Health Syst Pharm. 73(1 ):e6-e13. In some embodiments, the chimeric bispecific binding member is a bivalent single chain polypeptides. See, e.g. Thirion, et al. (1996) European J. of Cancer Prevention 5(6) :507-51 1 ; DeKruif and Logenberg (1996) J. Biol. Chem 271 (13)7630-7634; and Kay, et al. United States Patent Application Publication Number 2015/0315566 published November 5, 2015. In some instances, a chimeric bispecific binding member may be a bispecific T cell engager (BiTE). A BiTE is generally made by fusing a specific binding member (e.g., a scFv) that binds an antigen to a specific binding member (e.g., a scFv) with a second binding domain specific for a T cell molecule such as CD3. In some instances, a chimeric bispecific binding member may be a CAR T cell adapter. As used herein, by “CAR T cell adapter” is meant an expressed bispecific polypeptide that binds the antigen recognition domain of a CAR and redirects the CAR to a second antigen. Generally, a CAR T cell adapter will have to binding regions, one specific for an epitope on the CAR to which it is directed and a second epitope directed to a binding partner which, when bound, transduces the binding signal activating the CAR. Useful CAR T cell adapters include but are not limited to e.g., those described in Kim et al. (2015) J Am Chem Soc. 137(8):2832-5; Ma et al. (2016) Proc Natl Acad Sci U S A. 1 13(4):E450-8 and Cao et al. (2016) Angew Chem Int Ed Engl. 55(26) :7520-4.
[0056] In some embodiments, a linker polypeptide molecule is optionally incorporated into the CAR between the antigen binding domain and the transmembrane domain to facilitate antigen binding. Moritz and Groner (1995) Gene Therapy 2(8) 539-546. In one embodiment, the linker is the hinge region from an immunoglobulin, e.g. the hinge from any one of IgG 1 , lgG2a, lgG2b, lgG3, lgG4, particularly the human protein sequences. Alternatives include the CH2CH3 region of immunoglobulin and portions of CD3. In those instances where the ABD is an scFv, an IgG hinge is effective. In some embodiments the linker comprises the amino acid sequence (G4S)n where n is 1 , 2, 3, 4, 5, etc., and in some embodiments n is 3.
[0057] CARs useful in the practice of the present invention further comprise a transmembrane domain joining the ABD (or linker, if employed) to the intracellular cytoplasmic domain of the CAR. The transmembrane domain is comprised of any polypeptide sequence which is thermodynamically stable in a eukaryotic cell membrane. The transmembrane spanning domain may be derived from the transmembrane domain of a naturally occurring membrane spanning protein or may be synthetic. In designing synthetic transmembrane domains, amino acids favoring alpha-helical structures are preferred. Transmembrane domains useful in construction of CARs are comprised of approximately 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 22, 23, or 24 amino acids favoring the formation having an alpha-helical secondary structure. Amino acids having a to favor alpha-helical conformations are well known in the art. See, e.g Pace, etal. (1998) Biophysical Journal 75: 422-427. Amino acids that are particularly favored in alpha helical conformations include methionine, alanine, leucine, glutamate, and lysine. In some embodiments, the CAR transmembrane domain may be derived from the transmembrane domain from type I membrane spanning proteins, such as CD3^, CD4, CD8, CD28, etc.
[0058] The cytoplasmic domain of the CAR polypeptide comprises one or more intracellular signal domains. In one embodiment, the intracellular signal domains comprise the cytoplasmic sequences of the T-cell receptor (TCR) and co-receptors that initiate signal transduction following antigen receptor engagement and functional derivatives and sub-fragments thereof. A cytoplasmic signaling domain, such as those derived from the T cell receptor ^-chain, is employed as part of the CAR in order to produce stimulatory signals for T lymphocyte proliferation and effector function following engagement of the chimeric receptor with the target antigen. Examples of cytoplasmic signaling domains include but are not limited to the cytoplasmic domain of CD27, the cytoplasmic domain S of CD28, the cytoplasmic domain of CD137 (also referred to as 4-1 BB and TNFRSF9), the cytoplasmic domain of CD278 (also referred to as ICOS), p110a, p, or 5 catalytic subunit of PI3 kinase, the human CD3 - chain, cytoplasmic domain of CD134 (also referred to as 0X40 and TNFRSF4), FceR1 y and chains, MB1 (Iga) chain, B29 (IgP) chain, etc.), CD3 polypeptides (5, A and E), syk family tyrosine
kinases (Syk, ZAP 70, etc.), src family tyrosine kinases (Lek, Fyn, Lyn, etc.) and other molecules involved in T-cell transduction, such as CD2, CD5 and CD28.
[0059] In some embodiments, the CAR may also provide a co-stimulatory domain. The term “co-stimulatory domain”, refers to a stimulatory domain, typically an endodomain, of a CAR that provides a secondary non-specific activation mechanism through which a primary specific stimulation is propagated. The co-stimulatory domain refers to the portion of the CAR which enhances the proliferation, survival or development of memory cells. Examples of costimulation include antigen nonspecific T cell co-stimulation following antigen specific signaling through the T cell receptor and antigen nonspecific B cell co-stimulation following signaling through the B cell receptor. Co-stimulation, e.g., T cell co-stimulation, and the factors involved have been described in Chen & Flies. (2013) Nat Rev Immunol 13(4):227-42. In some embodiments of the present disclosure, the CSD comprises one or more of members of the TNFR superfamily, CD28, CD137 (4-1 BB), CD134 (0X40), Dap10, CD27, CD2, CD5, ICAM- 1 , LFA-1 (CD1 1 a/CD18), Lek, TNFR-I, TNFR-II , Fas, CD30, CD40 or combinations thereof.
[0060] In some embodiments, the intracellular domain of the CARs of the instant disclosure comprises an interleukin-2 receptor beta-chain (IL-2Rbeta or IL-2R-beta) cytoplasmic domain. In some embodiments, the IL-2Rbeta domain is truncated. In some embodiments, the IL- 2Rbeta cytoplasmic domain comprises one or more STAT5-recruitment motifs. In some embodiments, the CAR comprises one or more STAT5-recruitment motifs outside the IL- 2Rbeta cytoplasmic domain. In an embodiment, the IL-2R-beta cytoplasmic domain comprises one or more STAT5- recruitment motifs. Exemplary STAT5 -recruitment motifs are provided by Passerini et al. (2008) STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25+ effector T cells. International Immunology, Vol. 20, No. 3, pp. 421 -431 , and by Kagoya et al. (2018) A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nature Medicine doi: I0. IO38/nm.4478.
[0061] CARs are often referred to as first, second, third or fourth generation. The term first- generation CAR refers to a CAR wherein the cytoplasmic domain transmits the signal from antigen binding through only a single signaling domain, for example a signaling domain derived from the high-affinity receptor for IgE FcaRly, or the CD3<J chain. The domain contains one or three immunoreceptor tyrosine-based activating motif(s) [ITAM(s)] for antigendependent T-cell activation. The ITAM-based activating signal endows T-cells with the ability to lyse the target tumor cells and secret cytokines in response to antigen binding. Second- generation CARs include a co-stimulatory signal in addition to the CD3T signal. Coincidental delivery of the delivered co-stimulatory signal enhances cytokine secretion and antitumor activity induced by CAR-transduced T-cells. The co-stimulatory domain is usually be
membrane proximal relative to the CD3^ domain. Third-generation CARs include a tripartite signaling domain, comprising for example a CD28, CD3^, 0X40 or 4-1 BB signaling region. In fourth generation, or “armored car” CAR T-cells are further gene modified to express or block molecules and/or receptors to enhance immune activity.
[0062] Examples of intracellular signaling domains comprising may be incorporated into the CAR of the present invention include (amino to carboxy): CD3^; CD28 - 41 BB - CD3^; CD28 - 0X40 - CD3 ; CD28 - 41 BB - CD3^; 41 BB -CD-28 - CD3 and 41 BB - CD3^.
[0063] The term CAR includes CAR variants including but not limited split CARs, ON-switch CARS, bispecific or tandem CARs, inhibitory CARs (iCARs) and induced pluripotent stem (iPS) CAR-T cells.
[0064] The term “Split CARs” refers to CARs wherein the extracellular portion, the ABD and the cytoplasmic signaling domain of a CAR are present on two separate molecules. CAR variants also include ON-switch CARs which are conditionally activatable CARs, e.g., comprising a split CAR wherein conditional hetero-dimerization of the two portions of the split CAR is pharmacologically controlled. CAR molecules and derivatives thereof (i.e., CAR variants) are described, e.g., in PCT Application Nos. US2014/016527, US1996/017060, US2013/063083; Fedorov et al. Sci Transl Med (2013) ;5(215):215ra172; Glienke et al. Front Pharmacol (2015) 6:21 ; Kakarla & Gottschalk 52 Cancer J (2014) 20(2):151 -5; Riddell et al. Cancer J (2014) 20(2):141 -4; Pegram et al. Cancer J (2014) 20(2):127-33; Cheadle et al. Immunol Rev (2014) 257(1 ):91 -106; Barrett et al. Annu Rev Med (2014) 65:333-47; Sadelain et al. Cancer Discov (2013) 3(4):388-98; Cartellieri et al., J Biomed Biotechnol (2010) 956304; the disclosures of which are incorporated herein by reference in their entirety.
[0065] The term “bispecific or tandem CARs” refers to CARs which include a secondary CAR binding domain that can either amplify or inhibit the activity of a primary CAR.
[0066] The term “inhibitory chimeric antigen receptors” or “iCARs” are used interchangeably herein to refer to a CAR where binding iCARs use the dual antigen targeting to shut down the activation of an active CAR through the engagement of a second suppressive receptor equipped with inhibitory signaling domains of a secondary CAR binding domain results in inhibition of primary CAR activation. Inhibitory CARs (iCARs) are designed to regulate CAR- T cells activity through inhibitory receptors signaling modules activation. This approach combines the activity of two CARs, one of which generates dominant negative signals limiting the responses of CAR-T cells activated by the activating receptor. iCARs can switch off the response of the counteracting activator CAR when bound to a specific antigen expressed only by normal tissues. In this way, iCARs-T cells can distinguish cancer cells from healthy ones, and reversibly block functionalities of transduced T cells in an antigen-selective fashion. CTLA- 4 or PD-1 intracellular domains in iCARs trigger inhibitory signals on T lymphocytes, leading to less cytokine production, less efficient target cell lysis, and altered lymphocyte motility.
[0067] The term “tandem CAR” or “TanCAR” refers to CARs which mediate bispecific activation of T cells through the engagement of two chimeric receptors designed to deliver stimulatory or costimulatory signals in response to an independent engagement of two different tumor associated antigens.
Source Cells
[0068] Typically, the chimeric antigen receptor T-cells (CAR-T cells) are T-cells which have been recombinantly modified by transduction with an expression vector encoding a CAR in substantial accordance with the teaching above. As disclosed above, a Treg cell, or a CD4+ T cells modified by introduction of a FoxP3 coding sequence may be used. T cells for engineering as described above are collected from a subject or a donor may be separated from a mixture of cells by techniques that enrich for desired cells, or may be engineered and cultured without separation.
[0069] A population of cells comprising T regs can be isolated from whole blood. A population of cells comprising Tregs can be isolated from a peripheral blood apheresis product. A population of cells comprising Tregs can be isolated from a population of cells previously enriched and/or depleted for one or more other cell types, e.g., isolated from a population of cells depleted of CD34+ cells. In some embodiments, Tregs are isolated from the flow-through fraction of a CD34+ MACS selection.
[0070] The number of Tregs in a population of cells can be determined, for example, by flow cytometry, where Tregs can be identified as, for example, CD4+CD25+CD12710 or CD4+FOXP3+. Dose calculations can be adjusted based on measures of cell viability measurements, e.g., viability determined via flow cytometry with propidium iodide or 7-AAD, or via trypan blue exclusion.
[0071] An appropriate solution may be used for dispersion or suspension. Such solution will generally be a balanced salt solution, e.g. normal saline, PBS, Hank’s balanced salt solution, etc., conveniently supplemented with fetal calf serum or other naturally occurring factors, in conjunction with an acceptable buffer at low concentration, generally from 5-25 mM. Convenient buffers include HEPES, phosphate buffers, lactate buffers, etc. Techniques for affinity separation may include magnetic separation, using antibody-coated magnetic beads, affinity chromatography, cytotoxic agents joined to a monoclonal antibody or used in conjunction with a monoclonal antibody, e.g., complement and cytotoxins, and "panning" with antibody attached to a solid matrix, e.g., a plate, or other convenient technique. Techniques providing accurate separation include fluorescence activated cell sorters, which can have varying degrees of sophistication, such as multiple color channels, low angle and obtuse light scattering detecting channels, impedance channels, etc. The cells may be selected against dead cells by employing dyes associated with dead cells (e.g., propidium iodide). Any
technique may be employed which is not unduly detrimental to the viability of the selected cells. The affinity reagents may be specific receptors or ligands for the cell surface molecules indicated above. In addition to antibody reagents, peptide-MHC antigen and T cell receptor pairs may be used; peptide ligands and receptor; effector and receptor molecules, and the like.
[0072] The separated cells may be collected in any appropriate medium that maintains the viability of the cells, usually having a cushion of serum at the bottom of the collection tube. Various media are commercially available and may be used according to the nature of the cells, including dMEM, HBSS, dPBS, RPMI, Iscove’s medium, etc., frequently supplemented with fetal calf serum (FCS). The collected and optionally enriched cell population may be used immediately for genetic modification, or may be frozen at liquid nitrogen temperatures and stored, being thawed and capable of being reused. The cells will usually be stored in 10% DMSO, 50% FCS, 40% RPMI 1640 medium.
[0073] In some embodiments, the engineered cells comprise a complex mixture of immune cells, e.g., tumor infiltrating lymphocytes (TILs) isolated from an individual in need of treatment. See, for example, Yang and Rosenberg (2016) Adv Immunol. 130:279-94, “Adoptive T Cell Therapy for Cancer; Feldman et al (2015) Semin Oncol. 42(4):626-39 “Adoptive Cell Therapy- Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors”; Clinical Trial NCT01 174121 , “Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer”; Tran et al. (2014) Science 344(6184)641 -645, “Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer”.
[0074] In some embodiments, the engineered T cell is allogeneic with respect to the individual that is treated, e.g. see clinical trials NCT03121625; NCT03016377; NCT02476734; NCT02746952; NCT02808442. See for review Graham et al. (2018) Cells. 7(10) E155. In some embodiments an allogeneic engineered T cell is fully HLA matched. However not all patients have a fully matched donor and a cellular product suitable for all patients independent of HLA type provides an alternative. A universal ‘off the shelf’ CAR T cell product provides advantages in uniformity of harvest and manufacture.
[0075] The Treg cells may be cultured in vitro under various culture conditions, as disclosed herein. The cell population may be conveniently suspended in an appropriate nutrient medium, such as TexMACS, Iscove’s modified DMEM, RPMI-1640, etc., and as disclosed herein are supplemented with human serum. The culture may contain activation agent factors to which the cells are responsive.
Methods
[0076] Treg cells are usually obtained from a single donor, for example, obtained from mobilized peripheral blood apheresis of a single donor, although can be from combined donors. A donor and a recipient of the disclosure can be allogenic. A donor and a recipient of the
cryopreserved cells can be HLA matched. A donor and a recipient of the of the cryopreserved cells can be HLA mismatched, e.g. mismatched at 1 , 2, 3, 4, 5, or 6 of the major HLA alleles. A donor and a recipient of the cryopreserved cells can be haploidentical.
[0077] In some embodiments, a cell population of the disclosure can be obtained from whole blood. A cell population of the disclosure can be obtained from a peripheral blood apheresis product, for example, a mobilized peripheral blood apheresis product. A cell population of the disclosure can be obtained from at least one apheresis product, two apheresis products, three apheresis products, four apheresis products, five apheresis products, six apheresis products, or more.
Sorting
[0078] The population of cells, before or after introduction of a CAR, usually after introduction of a CAR, is selected for expression of CD39, where CD39- and CD39+ populations find use depending on the requirement for cytotoxicity in the application of the cells. CD39 (ectonucleoside triphosphate diphosphohydrolase-1 , gene: ENTPD1 ; protein: NTPDasel) is a cell surface enzyme with a catalytic site on the extracellular face, that catalyzes the hydrolysis of y- and |3-phosphate residues of triphospho- and diphosphonucleosides to the monophosphonucleoside derivative. The refseq for the human protein may be accessed at Genbank, NP_001091645, NP_001 157650, NP_001 157651 , NP_001 157653,
NP_001 157654.
[0079] Selection methods for cell populations can comprise methods involving positive or negative selection of a cell population of interest. Selection methods for cell populations can comprise affinity reagents, including but not limited to an antibody, a full-length antibody, a fragment of an antibody, a naturally occurring antibody, a synthetic antibody, an engineered antibody, a full-length affibody, a fragment of an affibody, a full-length affilin, a fragment of an affilin, a full-length anticalin, a fragment of an anticalin, a full-length avimer, a fragment of an avimer, a fulllength DARPin, a fragment of a DARPin, a full-length fynomer, a fragment of a fynomer, a full-length kunitz domain peptide, a fragment of a kunitz domain peptide, a full- length monobody, a fragment of a monobody, a peptide, or a polyaminoacid. In some embodiments, the affinity reagent is directly conjugated to a detection reagent and/or purification reagent. In some cases, the detection reagent and purification reagent are the same. In other cases, the detection reagent and purification reagent are different. For example, the detection reagent and/or purification reagent is fluorescent, magnetic, or the like. In some cases, the detection reagent and/or purification reagent is a magnetic particle for column purification. For example, magnetic column purification may be performed using the Miltenyi system (CliniMACs) of columns, antibodies, buffers, preparation materials and reagents
[0080] Affinity reagents can comprise immunoaffinity reagents, utilizing the binding specificity of antibodies or fragments or derivatives thereof to positively or negatively select for a cell population of interest. Selection methods for cell populations can comprise an affinity agent and a column, such as magnetic activated cell sorting (MACS) with specific antibodies and microbeads. Selection methods for cell populations can comprise fluorescent activated cell sorting (FACS), with cell populations sorted based on staining profiles with one or more fluorescently-conjugated antibodies. Selection methods for cell populations can comprise physical adsorption, for example, physical adsorption of T cells to protein ligands such as lectins.
[0081] A large number of anti-human CD-39 antibodies are commercially available and can find use for this purpose, including without limitation, antibodies sold by Amcam: Rabbit monoclonal [EPR26473-58] to CD39; Rabbit monoclonal [EPR20627] to CD39; Mouse monoclonal [AC2] to CD39; Rabbit monoclonal [EPR20461 ] to CD39; Rabbit monoclonal [EPR3678(2)] to CD39; Rabbit monoclonal [EPR26473-58] to CD39; Mouse monoclonal [IMG17B5F11] to CD39; Mouse monoclonal [A1] to CD39; APC Mouse monoclonal [TU66] to CD39; FITC Mouse monoclonal [A1] to CD39; and PE Mouse monoclonal [TU66] to CD39; antibodies sold by Invitrogen: CD39 Monoclonal Antibody (eBioAl (A1 )); CD39 Recombinant Rabbit Monoclonal Antibody (JA90-36); sold by LSBio: CD39 Mouse anti-Human Monoclonal (aa38-307) (2B10) Antibody, D39 Mouse anti-Human Monoclonal (BU61 ) Antibody, CD39 Antibody (clone A1 ), CD39 Mouse anti-Human Monoclonal (6H12F9) Antibody, CD39 Antibody (clone BU61 ); and the like.
[0082] A population of cells comprising CAR-Tregs can be selected using magnetic activated cell sorting (MACS). A population of cells comprising Tregs can be selected using fluorescent activated cell sorting (FACS). A population of cells comprising Tregs can be selected using multiple procedures, for example, multiple MACS selections, multiple FACS selections, or a combination of MACS and FACS selections.
[0083] In some embodiments the cells are first enriched by CD25 expression by CliniMACS immunomagnetic selection, followed by flow cytometric sorting for CD4+, CD127l0/ne9 expression. The resulting product is enriched for Tregs defined phenotypically as CD4+, CD25+, CD127l0/ne9 and expressing the transcription activator FoxP3. FoxP3 detection is used only to assess the percentage of CAR-Tregs in samples drawn from the final cellular product for infusion. The final population is selected into CD39 positive and negative fractions.
[0084] The cells are characterized by their expression of cell surface markers. For several of these markers, the expression is low or intermediate in level. While it is commonplace to refer to cells as “positive” or “negative” for a particular marker, actual expression levels are a quantitative trait. The number of molecules on the cell surface can
vary by several logs, yet still be characterized as “positive”. Characterization of the level of staining permits subtle distinctions between cell populations.
[0085] The staining intensity of cells can be monitored by flow cytometry, where lasers detect the quantitative levels of fluorochrome (which is proportional to the amount of cell surface antigen bound by the antibodies). Flow cytometry, or FACS, can also be used to separate cell populations based on the intensity of antibody staining, as well as other parameters such as cell size and light scatter. Although the absolute level of staining may differ with a particular fluorochrome and antibody preparation, the data can be normalized to a control.
[0086] In order to normalize the distribution to a control, each cell is recorded as a data point having a particular intensity of staining. These data points may be displayed according to a log scale, where the unit of measure is arbitrary staining intensity. In one example, the brightest cells in a bone marrow sample are designated as 4 logs more intense than the cells having the lowest level of staining. When displayed in this manner, it is clear that the cells falling in the highest log of staining intensity are positive, while those in the lowest intensity are negative. The “low” staining cells, may fall in the 2-3rd log of staining intensity. An alternative control may utilize a substrate having a defined density of antigen on its surface, for example a fabricated bead or cell line, which provides the positive control for intensity.
Activation
[0087] The sorted CAR-Treg cells may be activated in vitro for a period of time of at least about 24 hours, and not more than about 48 hours at 37°C. The in vitro activation can be from about 24 hours, from about 26 hours, from about 28 hours, from about 30 hours, from about 32 hours, from about 34 hours from about 36 hours, up to about 48 hours, up to about 46 hours, up to about 44 hours, up to about 42 hours, up to about 40 hours, up to about 38 hours, and may be for about 24, about 30, about 36, about 42, about 48 hours. For activation the cells are suspended in medium at a concentration of from about 0.9 x 105 viable cells/ml from about 1 x 106, up to about 2 x 106; up to about 3 x 106 and may be at a concentration of from about 1.1 x 106 to about 2 x 106 viable cells/ml, e.g. at about 1.1 x 106; 1 .2 x 106; 1 .3 x 106; 1 .4 x 106; 1.5 x 106; 1 .6 x 106; 1.7 x 106; 1.8 x 106; 1 .9 x 106; 2 x 106.
[0088] The medium comprises an suitable cell medium, e.g. TexMACs™, etc., and effective dose of human serum, a T cell activating agent, e.g. TransAct™ (Miltenyi); and IL-2. Each of the reagents is generally GMP grade. Human serum may be present at a concentration of from about 5% to about 15% vol/vol, e.g. from about 6%, about 7%, about 8% about 9%, about 10% about 1 1 % about 12%, up to about 15%, up to about 14%, up to about 13%, up to about 13%, up to about 12%, and may be present at about 10% concentration. IL-2 is present at a concentration of from about 100 lU/ml up to about 5000 lU/ml, e.g. from about 100 IU, from about 200 IU, from about 300 IU, from about 400 IU, from about 500 IU, up to about 5000 IU,
up to about 4000 IU, up to about 3000 IU, up to about 2000 IU, up to about 1000 IU, and may be present at about 500 IU. TransAct™ may be added in accordance with the manufacturers’ guideline, e.g. diluted from about 1 :20 to about 1 :10, and may be 1 :17.5, 1 :15, 1 :12.5, etc.
Freezing
[0089] The activated Treg calls are optionally cryopreserved. Cryopreservation can comprise addition of a preservative agent (e.g., DMSO), and gradual cooling of cells in a controlled-rate freezer to prevent osmotic cellular injury during ice crystal formation. Cryopreservation can comprise commercial cryopreservation reagents and materials, for example, Cryobags and CryoStor® CS10. In some embodiments the cells are resuspended in Normosol-R, pH 7.4; with hydroxyethyl starch 30.5%; human serum albumin (HSA) 12%; and DMSO 7.5%. Cryopreserved cells can be stored for periods of time ranging from hours to years at low temperatures. Cryopreserved cells can be stored at ultralow temperatures, for example, -50 aC, -60 9C, -70 9C, -80 aC, -90 9C, -100 9C, -110 eC, -120 9C, -130 9C, -140 eC, -150 9C, -160 9C, 1709C, -180 9C, -190 aC, -196 eC, or less. Cryopreserved cells can be stored in storage devices comprising liquid nitrogen.
[0090] Post-thaw the cells are placed in a suitable medium comprising human serum and IL- 2, and may be activated a second time, in the absence of the T cell activating agent. For activation the cells are suspended in medium at a concentration of from about 0.9 x 105 viable cells/ml from about 1 x 106, up to about 2 x 106; up to about 3 x 106 and may be at a concentration of from about 1 .1 x 106 to about 2 x 106 viable cells/ml, e.g. at about 1 .1 x 106;
1 .2 x 106; 1 .3 x 106; 1 .4 x 106; 1 .5 x 106; 1 .6 x 106; 1 .7 x 106; 1 .8 x 106; 1 .9 x 10s; 2 x 106. After the initial culture, a T cell activating agent, e.g. TransAct™ is added to the cells and the cell suspension returned to 37°C, 5% CO2 for a period of from about 12 to about 24 hours, e.g. from about 12 hours, from about 14 hours, from about 16 hours, from about 18 hours, from about 20 hours, up to about 24 hours, up to about 22 hours, up to about 20 hours, up to about 18 hours, up to about 16 hours.
Administration
[0091] A population of cells comprising CD39+ CAR-Tregs or CD39 CAR-Tregs can be administered to a subject at a dose greater than at least about 1 x 104, 1 x 105, 2 x 105, 3 x
105, 4 x 105, 5 x 105, 6 x 105, 7 x 105, 8 x 105, 9 x 105, 1 x 106, 1.1 x 106, 1.2 x 106, 1 .3 x 106, 1 .4 x 106, 1.5 x 106, 1.6 x 106, 1 .7 x 106, 1.8 x 106, 1 .9 x 106, 2 x 106, 2.1 x 106, 2.2 x 106, 2.3 x 106, 2.4 x 106, 2.5 x 106, 2.6 x 106, 2.7 x 106, 2.8 x 106, 2.9 x 106, 3 x 106, 3.1 x 106, 3.2 x
106, 3.3 x 106, 3.4 x 106, 3.5 x 106, 3.6 x 106, 3.7 x 106, 3.8 x 106, 3.9 x 106, 4 x 106, 4.1 x 106,
4.2 x 106, 4.3 x 106, 4.4 x 106, 4.5 x 106, 4.6 x 106, 4.7 x 106, 4.8 x 106, 4.9 x 106, 5 x 106, 5.1 x 106, 5.2 x 106, 5.3 x 106, 5.4 x 106, 5.5 x 106, 5.6 x 106, 5.7 x 106, 5.8 x 106, 5.9 x 106, 6 x
106, 6.5 x 106, 7 x 106, 7.5 x 10®, 8 x 106, 8.5 x 106, 9 x 106, 9.5 x 106, 1 x 107, 1.5 x 107, 2 x
107, 2.5 x 107, 3 x 107, 3.5 x 107, 4 x 107, 4.5 x 107, 5 x 107, 5.5 x 107, 6 x 107, 6.5 x 107, 7 x
107, 7.5 x 107, 8 x 107, 8.5 x 107, 9 x 107, 9.5 x 107, 1 x 10s, 1 x 108, 1.5 x 108, 2 x 108, 2.5 x
108, 3 x 108, 3.5 x 108, 4 x 107, 4.5 x 108, 5 x 108, 5.5 x 108, 6 x 108, 6.5 x 108, 7 x 108, 7.5 x
108, 8 x 108, 8.5 x 108, 9 x 108, 9.5 x 108, 1 x 109, or more cells per kg of recipient body weight.
[0092] In some embodiments, a population of cells comprising CD39+ CAR-Tregs or CD39' CAR-Tregs administered to a subject can be administered at a dose of at most about 1 x 104, 1 x 105, 2 x 105, 3 x 105, 4 x 105, 5 x 105, 6 x 105, 7 x 105, 8 x 105, 9 x 105, 1 x 106, 1 .1 x 106, 1 .2 x 106, 1.3 x 106, 1.4 x 106, 1 .5 x 106, 1.6 x 106, 1 .7 x 106, 1 .8 x 106, 1.9 x 106, 2 x 106, 2.1 x 106, 2.2 x 106, 2.3 x 106, 2.4 x 106, 2.5 x 10®, 2.6 x 10®, 2.7 x 10®, 2.8 x 10®, 2.9 x 10®, 3 x 10®, 3.1 x 10®, 3.2 x 10®, 3.3 x 10®, 3.4 x 10®, 3.5 x 10®, 3.6 x 10®, 3.7 x 10®, 3.8 x 10®, 3.9 x 10®, 4 x 10®, 4.1 x 10®, 4.2 x 10®, 4.3 x 10®, 4.4 x 10®, 4.5 x 10®, 4.6 x 10®, 4.7 x 10®, 4.8 x 10®, 4.9 x 10®, 5 x 10®, 5.1 x 10®, 5.2 x 10®, 5.3 x 10®, 5.4 x 10®, 5.5 x 10®, 5.6 x 10®, 5.7 x 10®, 5.8 x 10®, 5.9 x 10®, 6 x 10®, 6.5 x 10®, 7 x 10®, 7.5 x 10®, 8 x 10®, 8.5 x 10®, 9 x 10®, 9.5 x 10®, 1 x
107, 1.5 x 107, 2 x 107, 2.5 x 107, 3 x 107, 3.5 x 107, 4 x 107, 4.5 x 1 O7, 5 x 107, 5.5 x 1 O7, 6 x
107, 6.5 x 107, 7 x 1 O7, 7.5 x 107, 8 x 1 O7, 8.5 x 107, 9 x 107, 9.5 x 1 O7, 1 x 108, 1 x 108, 1.5 x
108, 2 x 108, 2.5 x 108, 3 x 108, 3.5 x 108, 4 x 107, 4.5 x 108, 5 x 108, 5.5 x 108, 6 x 108, 6.5 x
108, 7 x 108, 7.5 x 108, 8 x 108, 8.5 x 108, 9 x 108, 9.5 x 108, 1 x 109, or less cells per kg of recipient body weight, where Tregs are defined as CD4+CD25+CD127dim, CD3+CD4+CD25+, CD3+ CD4+ CD25+ CD127dim, CD3+ CD4+ CD25+ CD127dim FOXP3+,
CD3+FOXP3+, CD3+CD4+FOXP3+, CD3+ CD4+CD25+FOXP3+, CD3+CD25+FOXP3+, CD3+CD25+CD127dim, CD4+CD25+, CD4+CD25+CD127dimFOXP3+, FOXP3+, CD4+FOXP3+, CD4+CD25+FOXP3+, CD25+FOXP3+, or CD25+ CD127dim.
[0093] A population of cells comprising CD39+ CAR-Tregs or CD39’ CAR-Tregs of the disclosure can comprise, for example, greater than at least about 50%, 51%, 52%, 53%, 54%,
55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%,
71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%,
87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more FOXP3+ cells as a percentage of total cells, nucleated cells, or CD45+ cells, or CD4+CD25+CD127dim cells as a percentage of total cells, nucleated cells, or CD45+ cells, or as a percentage of total cells, nucleated cells, or CD45+ cells.
[0094] A population of cells comprising CD39+ CAR-Tregs or CD39’ CAR-Tregs of the disclosure can have a defined level of contaminating non-Treg cells. For example, greater than at least about 1 x 102, 2 x 102, 3 x 102, 4 x 102, 5 x 102, 6 x 102, 7 x 102, 8 x 102, 9 x 102, 1 x 103, 2 x 103, 3 x 103, 4 x 103, 5 x 103, 6 x 103, 7 x 103, 8 x 103, 9 x 103, 1 x 104, 2 x 104, 3 x 104, 4 x 104, 5 x 104, 6 x 104, 7 x 104, 8 x 104, 9 x 104, 1 x 105, or more non-T reg cells per kg
of recipient body weight can be present in population of cells comprising Tregs of the disclosure, where non-Treg cells are FOXP3- or CD127+/bright.
[0095] In some embodiments, at most about 1 x 102, 2 x 102, 3 x 102, 4 x 102, 5 x 102, 6 x 102, 7 x 102, 8 x 102, 9 x 102, 1 x 103, 2 x 103, 3 x 103, 4 x 103, 5 x 103, 6 x 103, 7 x 103, 8 x 103, 9 x 103, 1 x 104, 2 x 104, 3 x 104, 4 x 104, 5 x 104, 6 x 104, 7 x 104, 8 x 104, 9 x 104, 1 x 105, or less non- comprising CD39+ CAR-Tregs or CD39’ CAR-Tregs cells per kg of recipient body weight are present in a population of cells comprising Tregs of the disclosure, where non-Treg cells are FOXP3- or CD127+/bright.
[0096] A population of cells comprising CD39+ CAR-Tregs or CD39" CAR-Tregs of the disclosure can comprise, for example, greater than at least about 0.001 %, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008% 0.009%, 0.01 %, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1 %, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1 %, 1 .1 %, 1 .2%, 1 .3%, 1 .4%, 1 .5%, 1 .6%, 1 .7%, 1 .8%, 1 .9%, 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, 3.1 %, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or more non-Treg cells as a percentage of total cells, nucleated cells, or CD45+ cells, where non-Treg cells are FOXP3- or CD127+/bright.
[0097] In some embodiments, a population of cells comprising CD39+ CAR-Tregs or CD39" CAR-Tregs of the disclosure comprises at most about 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008% 0.009%, 0.01 %, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1 %, 1.1 %, 1 .2%, 1 .3%, 1 .4%, 1 .5%, 1 .6%, 1 .7%, 1 .8%, 1 .9%, 2%, 2.1 %, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or less non-Treg cells as a percentage of total cells, nucleated cells, or CD45+ cells, where non-Treg cells are FOXP3- or CD127+/bright.
Conditions for treatment
[0098] CAR Treg cells are useful in a variety of conditions, including, for example, treatment of cancer, in association with hematopoietic stem cell transplantation (HCT), for example to reduce graft v host disease, to reduce allograft rejection, and the like. In some embodiments a condition to be treated is an autoimmune disease, allergic disease, or inflammatory disease. For example, a population of cells comprising CD39 selected CAR-Tregs can be administered to an HCT recipient subject, and the population of CD39 selected CAR-Tregs can serve to reduce or prevent GVHD in the HCT recipient subject.
[0099] Graft-versus-host disease (GVHD) is an inflammatory disease that can occur in the allogenic transplant setting. GVHD involves donor cells (graft) attacking recipient cells (host). GVHD can be classified into acute GVHD (aGVHD) and chronic GVHD (cGVHD). aGVHD typically occurs in the first 3 months after transplantation. aGVHD can be life-threatening and
can involve, for example, the skin, the intestines, and/or the liver. cGVHD typically occurs after the first 3 months following transplant. cGVHD is a major source of late treatment-related complications, and can be life-threatening. In addition to inflammation, cGVHD can lead to the development of fibrosis, which can result in functional disability.
[00100] The early morbidity and mortality associated with acute graft versus host disease (aGVHD) is a major factor limiting the success of HCT, as is the long-term morbidity associated with chronic GVHD (cGVHD). The incidence of aGVHD following allogeneic HCT from an HLA-matched sibling donor (MSD) is 20 to 60%, despite the use of various immunosuppressive agents such as tacrolimus, cyclosporine, methotrexate, mycophenolate, anti-thymocyte globulin and corticosteroids. Approximately one-third of patients who undergo allogeneic HCT using a MSD and a T cell replete graft will develop chronic GVHD.
[00101] GVHD severity can be graded, for example, using the Glucksberg grade (l-IV) or the International Bone Marrow Transplant Registry (IBMTR) grading system (A-D). The severity of acute GVHD is determined by an assessment of the degree of involvement of the skin, liver, and gastrointestinal tract. The stages of individual organ involvement are combined with (Glucksberg) or without (IBMTR) the patient’s performance status to produce an overall grade, which can have prognostic significance. Grading is important in terms of assessing the response to prophylaxis or treatment, impact upon survival, and association with graft-versus- leukemia effect.
[00102] Grade l(A) GVHD is characterized as mild disease, grade ll(B) GVHD as moderate, grade lll(C) as severe, and grade IV(D) life-threatening. The IBMTR grading system defines the severity of acute GVHD as follows: Grade A: stage 1 skin involvement alone (maculopapular rash over <25 percent of the body) with no liver or gastrointestinal involvement; Grade B: stage 2 skin involvement, stage 1 to 2 gut or liver involvement; Grade C: stage 3 involvement of any organ system (generalized erythroderma; bilirubin 6.1 to 15.0 mg/dL; diarrhea 1500 to 2000 mL/day); Grade D: stage 4 involvement of any organ system (generalized erythroderma with bullous formation; bilirubin >15 mg/dL; diarrhea >2000 mL/day OR pain OR ileus). Patients with moderate to severe GVHD have a significantly higher mortality rate compared with those with milder disease, for example, estimated five year survival for patients with grade III (C) aGVHD is 25%, while for patients with grade IV (D) estimated five year survival is 5%.
[00103] Management of GVHD may require immunosuppressive therapy (for example, high dose corticosteroids, prolonged administration of immunosuppressants) or cytotoxic mediations, all of which are associated with toxicity. In many cases, immunosuppressive therapies can fail to effectively treat GVHD, or can result in increased susceptibility to infection, or blunted anti-tumor immunity.
[00104] In some embodiments, administration of the CD39 selected CAR-Treg cells, particularly CD39+ CAR-Treg cells of the disclosure disclosed herein prevent or reduce GVHD in an HCT recipient subject. For example, the methods disclosed herein can prevent any manifestation of GVHD in a subject receiving HCT. In some embodiments the CAR of such cells is targeted to a transplantation alloantigen, e.g. an HLA Class I or HLA Class II antigen.
[00105] The methods disclosed herein can prevent, for example, any GVHD of stage 1 or above, any GVHD of stage 2 or above, any GVHD of stage 3 or above, or any GVHD of stage 4 in subjects receiving HCT.
[00106] Type 1 diabetes (T1 D) is an autoimmune disorder characterized by insulin deficiency due to the destruction of pancreatic p cells. Studies have shown reduced immune suppressive functionality of Tregs in patients with T1 D. This observation and the success of Treg transplantation in maintaining immunologic tolerance has led to the application of Treg infusion in T1 D patients to rescue remaining cells. Infusion of expanded antigen-specific Tregs showed promising results in animal models in blocking and reversing diabetes.
[00107] In some embodiments, administration of the CD39 selected CAR-Treg cells, particularly CD39+ CAR-Treg cells of the disclosure disclosed herein prevent or reduce T1 D in a recipient. For example, the methods disclosed herein can prevent any manifestation of T1 D in a subject. In some embodiments the CAR of such cells is targeted to a pancreatic antigen, e.g. glutamic acid decarboxylase (GAD), insulin, HPi2, immunodominant GAD65 beta-cell epitopes, etc.
[00108] In some embodiments, the autoimmune disease, allergic disease, or inflammatory disease is transplant rejection. In some embodiments, the transplant rejection occurs in response to transplanted blood, bone marrow, bone, skin, heart, kidney, lung, muscle, heart or liver. In some embodiments, the transplant rejection is hyperacute rejection. In some embodiments, the transplant rejection is acute rejection. In some embodiments, the transplant rejection is chronic rejection. In some embodiments the transplant is allogeneic islet transplantation.
[00109] In some embodiments, the CD39 selected CAR-Tregs of the disclosure comprise a CAR that targets a human leukocyte antigen. In some embodiments, the HLA targeted by the CAR is the same HLA allele as a donor. For example, the donor is HLA-A*2:0l and the CAR- Treg targets HLA- A* 2:0.1 In some embodiments, the human leukocyte antigen targeted by the CAR is the same HLA allele as a recipient. All alleles of HLA-A, HLA-B and HLA-C are envisaged as within the scope of the disclosure.
[001 10] In some embodiments, the method increases CD45+ cell engraftment, increases overall survival, decreases serum inflammatory cytokines or a combination thereof. In some
embodiments, the method decreases spleen inflammation, liver inflammation, lung inflammation, inflammation of the central nervous system (CNS), inflammation of the skin, inflammation of the pancreas, inflammation of the kidney, inflammation of the pleural cavity, inflammation of the gastrointestinal tract, inflammation of the genitourinary tract, or inflammation of the pelvis. In some embodiments, the disclosure provides a method for reducing transplant rejection in a patient transplanted with hematopoietic stem cells, bone marrow cells, or a solid organ, comprising providing administering the CD39 selected CAR- Tregs to the patient.
[001 11] In some cases, the method prevents allograft rejection, improving upon concepts described in Noyan et al. (2017) Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor. Am. J. Transplantation 2017; 17: 917-930.
EXPERIMENTAL
Example 1
Materials and methods
[001 12] Cell purification, in vitro expansion, and characterization. In this study, Fresh peripheral blood mononuclear cell (PBMC) samples were isolated from LRS chambers/buffy coats of healthy donors purchased from Stanford Blood Centers (Palo Alto, CA) or and 50 to 70 mL freshly drawn peripheral blood from patients with Type 1 diabetes(T1 D). Human peripheral blood mononuclear cells (PBMC) were isolated from blood by gradient centrifugation on Ficoll-Hypaque gradients (GE Healthcare Bioscience). Natural regulatory T cells (nTregs; CD3+ CD4+ CD8-CD25highCD127low) and autologous CD4+ T cells required for suppression assays were isolated by enrichment from PBMCs using EasySep Human CD4+CD127lowCD25+ Regulatory T Cell Isolation Kit (StemCell Technologies) according to the manufacturer’s instructions.
[001 13] The isolated Treg then were purified with fluorescence-activated cell sorting using the following gates: lymphocytes, single cells, live (aqua-), whole Treg CD3+CD4+CD8- CD25hiCD127-, CD39+ Treg CD3+CD4+CD8-CD25hiCD127-CD39+ and CD39- Treg CD3+CD4+CD8-CD25hiCD127-CD39- The monoclonal antibody combinations were as listed on Table 1. The FACS-based cell sorting was performed at Stanford Shared FACS Facility using a FACSAria™ II Cell Sorter (Beckton Dickinson) and had a purity of >99.0%.
[001 14] Sorted populations were expanded in X-VIVO™ 15 Chemically Defined Medium, with gentamicin and phenol red (Lonza) supplemented with 10% heat inactivated Human male AB serum (Sigma-Aldrich) and 10% L-glutamine(HyClone™), 10% Sodium Pyruvate(Gibco) and 10% non-essential amino acids(NEAA)(Fisher) in the presence of recombinant human IL-2 (rlL-2, PeproTech) (100 lU/ml for Teff; 500 lU/ml for Tregs), expanded by using Dynabeads® Human T-Activator CD3/CD28(Gibco) according to the manufacturer’s instructions. Tregs
have been cultured for 12 consecutive days, checked every 6 days for purity by FACS analysis (CD4+FoxP3+ cells constantly > 90%), washed, and then transfected. To evaluate the purity of Tregs isolated by this cell-sorting scheme, they were stained with anti-FoxP3 (Clone 206D, BioLegend) in FoxP3 staining buffer (eBioscience). Flow cytometry data were acquired on an LSRII or FACS Caliber (Becton Dickinson); FACS Diva software (BD) and FlowJo version v10 software (Treestar) were used for analysis.
[001 15] Transfection of Tregs. For T cell activation, expanded Treg cells were activated using Dynabeads® Human T-Activator CD3/CD28(Gibco) in a bead: cell=1 : 3 ratio for 1 -3 days at 37°C with 5% CO2 in the presence of 500 lU/ml recombinant human IL-2 (rhlL-2) (R&D Systems). Treg were harvested and washed with PBS. A total of 2 x 106 activated Treg was electroporated with a Neon Transfection System (Invitrogen) under the following conditions: voltage (2400 V), width (10 ms), pulses (three), 100-pil tip, and Buffer T. Cells were transfected with 2 pg of HLA-A2 CAR mRNA or 2 pg of 1 x9Q mRNA. After electroporation, cells were plated in a 6-well plate in 2 ml of CM RPMI 1640 with 500 IU rhlL-2/ml without antibiotics. The CAR construct expression efficacy was checked using Flag or Tetra HLA-A2. Cells were then used for functional assay described below.
[001 16] Glucose-induced insulin-secretion test. Islets after coculture with CAR-Treg for 48 hours were preincubated in a modified Krebs-Ringer Bicarbonate buffer (KRBB) containing 1 15 mmol/l NaCI, 5 mmol/l KCI, 24 mmol/l NaHCOs, 2.2 mmol/l CaCL, 1 mmol/l MgCL, 20 mmol/l HEPES, 2 g/l human serum albumin (Cealb, Sanquin, The Netherlands), pH 7.4 for 2 hours. Subsequently, islets were cultured in Krebs-Ringer bicarbonate buffer (KRBB) with 1 % bovine serum albumin (BSA) and with 2.8 mM glucose for 1 hour. Then islets were cultured in KRBB containing 2.8 mM or 16.7 mM glucose for additional 2 hours at 37°C. Afterwards, the supernatants were collected. Insulin concentrations were determined in the supernatants using Human Insulin ELISA Kit(Sigma-Aldrich)
[001 17] Purified Human Pancreatic Islet Viability Assessment Using Fluorescent Dyes and microscope. The viability was assessed fluorescein diacetate (FDA) and propidium iodide(PI). The concentrations are FDA(5mg/ml), Pl(2mg/ml). FDA passes through plasma membranes and is hydrolyzed by intracellular esterase to produce bright green fluorescent and identify viable cells. PI enters dead and dying cells and produces orange/red fluoresces. Briefly, the islet were collected in a tube, centrifuged, and suspended in 1 mL PBS. Afterwards, working solutions (1 .5 pL each) of FDA and PI were added to each tube, incubated for 15 min at room temperature, and the cells were washed with PBS to remove the unbound dye. Then, live dead imaging was performed using a fluorescence microscope (Leika in Dr. Justin Annes’ lab). CAR-Treg were labeled with CellTrace™ Violet (ThermoFisher Scientific) to be identified as blue. In addition, quantitative assessment of the viability was performed by using cell counting kit-8 (Dojindo Molecular Technologies, Inc, Rockville, Maryland, USA).
[001 18] Purified Human Pancreatic Islet Viability Assessment Using flow. In a separate series of studies, islets were dispersed with Accumax - Cell Aggregate Dissociation Medium (Invitrogen™) and cocultured with CAR-Treg in 96-well plates at a density of 1 *105 dispersed islet cells for 48 hours. Then cells were collected and stained with FITC Annexin V Apoptosis Detection Kit with 7-AAD(BioLegend) according to the manufacturer’s instructions. Data were collected using a FACS Aria II analyzer and analyzed using Flowjo v10 software.
[001 19] Monocyte Viability Assessment Using flow. Monocytes were isolated by enrichment from PBMCs using EasySep Human Monocyte Isolation Kit (StemCell Technologies) according to the manufacturer’s instructions. The isolated monocyte were then purified with fluorescence-activated cell sorting using the following gates: lymphocytes, single cells, live (aqua-), CD14+HLA-DR+CD11 b+CD3-CD56-CD19- The monoclonal antibody combinations were as listed on Table 1. Monocyte were cocultured with CAR-Treg in 48-well plates at a density of 1 x106/ml for 48 hours. Then cells were collected and stained with FITC Annexin V Apoptosis Detection Kit with 7-AAD(BioLegend) according to the manufacturer's instructions, monocyte were gated on CD14+HLA-DR+CD11 b+lineage(CD3,CD56,CD19)-. Data were collected using a FACS Aria II analyzer and analyzed using Flowjo v10 software.
[00120] Tunel assay: Coverslips were coated (High performance coverslip 12mm dia 1.5h treated sterile super resolution, Neuvitro) with Poly-D-Lysine(Gibco). The coated sterile coverslips were placed into 12-well plate using sterile forceps, p Lox5 cells were plated onto sterilized glass coverslips after labeled with CellTrace™ Far Red Cell (Thermo Fisher Scientific) and cultured for 24 hours. Then CAR-Treg were seeded and cocultured with pLox5 cells for 24 hours. For detection of apoptosis, the coverslips were stained using the In situ Cell Death detection kit (Roche). Briefly, the coverslips were washed once gently with PBS, pH 7.2, avoiding removal of dying cells. The cells were fixed in room-temperature 4% paraformaldehyde (PFA) for one hours. And samples then were permeabilized with 0.1 % Triton X-100, 0.1 % sodium citrate, for 2 minutes at room temperature. 50 pl of TUNEL reaction solution (In Situ Cell Death Detection Kit, Fluorescein, Roche; Enzyme solution+Label solution) was added onto each coverslip and incubate at 37°C for 1 hour. Nuclei were stained with DAPI (100 ng/mL; MilliporeSigma). Negative controls for TUNEL staining included only 50ul label solution. Finally, the sections were analyzed using Leica SP8 White Light Confocal microscope with a 40x HC PL APO, CS2 oil objective lens (Stanford University Cell Sciences Imaging Facility). Images were evaluated for TUNEL staining using Leica LAS X software. The percentage of TUNEL positive cells was determined as the ratio of TUNEL positive cells to total nuclei x 100.
Table 1 : Antibodies used for flow cytometry.
Target Clone Fluorochrome Vendor RRID
CD3 OKT3 Alexa Fluor 488 BioLegend AB_571877
CD3 OKT3 APC BioLegend AB_1937212
CD3 OKT3 BV785 BioLegend AB_2563507
CD4 SK3 Alexa Fluor 700 BioLegend AB_2563150
CD4 OKT4 Alexa Fluor 488 BioLegend AB_571939
CD8 SK1 BUV805 BD Biosciences AB_2833078
CD8 SK1 APC/Cyanine7 BioLegend AB_2044006
CD25 BC96 PE/Dazzle™ 594 BioLegend AB 2734260
CD25 2A3 BUV395 BD Biosciences AB_2738556
CD127 A019D5 PerCP/Cyanine5.5 BioLegend AB_10897104
CD39 eBioAl BV605 BioLegend AB_2750430
CD45RO UCHL1 BUV395 BD Biosciences AB_2744410
CD45RO UCHL1 Alexa Fluor 488 BioLegend AB 528823
CD62L DREG-56 PE-Cy7 BioLegend AB_830801
PD-1 NAT105 BV785 BioLegend AB_2721562
Tim -3 F38-2E2 PE/Dazzle™ 594 BioLegend AB_2565886
LAG-3 11 C3C65 BV650 BioLegend AB_2632951
F0XP3 206D BV421 BioLegend AB_2565972
IL- 10 JES3-19F1 APC-R700 BD Biosciences AB_2870004
IFN-Y 4S.B3 BV605 BioLegend AB_2563881
TNF-a Mab11 APC BioLegend AB_315264
IL-4 MP4-25D2 PE BioLegend AB_315129
Granzyme B GB11 Alexa Fluor 647 BioLegend AB_2566333
Granzyme B QA16A02 APC/Fire™ 750 BioLegend AB 2728377
HLA-A2 BB7.2 PE BioLegend AB_1877227
HLA-A2 BB7.2 APC BioLegend AB_2561567
PD-L1 29E.2A3 PE-Cy7 BioLegend AB_2561687
CD209 9E9A8 Alexa Fluor 647 BioLegend AB_1 186092
CD14 M5E2 APC/Fire™ 750 BioLegend AB_2632660
CD163 GHI/61 PerCP/Cyanine5.5 BioLegend AB_2228986
CD16 G8 BUV395 BD Biosciences AB_2744293
CD206 19.2 BUV805 BD Biosciences AB_2871334
CD11c Bu15 BV421 BioLegend AB 2564485
Target Clone Fluorochrome Vendor RRID
CD11b ICRF44 BV605 BioLegend AB_2562021
CD86 IT2.2 BV785 BioLegend AB_2616794
HLA-DR L243 PE/Dazzle™ 594 BioLegend AB_2563646
HPx1 HIC0-3B3 Dy Light 405 Novus Biologicals
HPi2 HIC1 -2B4.2B Alexa Fluor 647 Novus Biologicals
[00121] The preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of the present invention is embodied by the appended claims.
Claims
1 . A method of selecting chimeric antigen receptor (CAR) regulatory T cells (Tregs) for reduced cytotoxicity, the method comprising: introducing into a population of Tregs a CAR targeted to an antigen of interest to generate a CAR-Treg population; selecting the CAR-Treg population for expression of CD39, wherein CD39+ cells have decreased cytotoxicity to the targeted cell population.
2. The method of claim 1 , wherein the reduction in cytotoxicity is at least 25%, at least 50%, at least 75% decrease, and may be a two-fold decrease in cytotoxicity or more.
3. The method of claim 1 or claim 2, wherein the T regs are administered to an individual in need thereof.
4. The method of claim 3, wherein the composition comprising Tregs are administered at a dose of from 104 cells/kg body weight to about 109 cells/kg body weight.
5. The method of claim 3 or claim 4, wherein the composition comprising Tregs comprises at least about 50% CD4+ CD25+ CD127l0 cells.
6. The method of any of claims 3-5, wherein the cells are administered for the treatment of an autoimmune disease or graft versus host disease.
7. A method of selecting chimeric antigen receptor (CAR) regulatory T cells (Tregs) for increased cytotoxicity, the method comprising: introducing into a population of Tregs a CAR targeted to an antigen of interest to generate a CAR-Treg population; selecting the CAR-Treg population for expression of CD39, wherein CD39- cells have increased cytotoxicity to the targeted cell population.
8. The method of claim 7, wherein the increase in cytotoxicity is at least 25%, at least 50%, at least 75% increase, and may be a two-fold increase in cytotoxicity or more.
9. The method of claim 7 or claim 8, wherein the T regs are administered to an individual in need thereof.
10. The method of claim 9, wherein the composition comprising T regs are administered at a dose of from 104 cells/kg body weight to about 109 cells/kg body weight.
1 1 . The method of claim 9 or claim 10, wherein the composition comprising Tregs comprises at least about 50% CD4+ CD25+ CD127l0 cells.
12. The method of any of claims 3-5, wherein the cells are administered for the treatment of transplant rejection or cancer.
13. A composition comprising a population of Tregs obtained by the method according to any of claims 1 -2 or 7-8.
14. A method of selecting genetically modified regulatory T cells (Tregs) for reduced cytotoxicity, the method comprising: introducing into a population of Tregs a construct targeted to an antigen of interest to generate a genetically modified Treg population; selecting the Treg population for expression of CD39, wherein CD39+ cells have decreased cytotoxicity to the targeted cell population.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263425109P | 2022-11-14 | 2022-11-14 | |
US63/425,109 | 2022-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024107410A1 true WO2024107410A1 (en) | 2024-05-23 |
Family
ID=91085230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/037215 WO2024107410A1 (en) | 2022-11-14 | 2023-11-13 | Cd39 selection for cytotoxicity of genetically engineered t regulatory cells |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024107410A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190038671A1 (en) * | 2016-02-04 | 2019-02-07 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
US20200330515A1 (en) * | 2017-10-17 | 2020-10-22 | The General Hospital Corporation | Methods and compositions relating to engineered regulatory t cells |
US20210268022A1 (en) * | 2020-02-11 | 2021-09-02 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
US20210338724A1 (en) * | 2020-02-11 | 2021-11-04 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
-
2023
- 2023-11-13 WO PCT/US2023/037215 patent/WO2024107410A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190038671A1 (en) * | 2016-02-04 | 2019-02-07 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
US20200330515A1 (en) * | 2017-10-17 | 2020-10-22 | The General Hospital Corporation | Methods and compositions relating to engineered regulatory t cells |
US20210268022A1 (en) * | 2020-02-11 | 2021-09-02 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
US20210338724A1 (en) * | 2020-02-11 | 2021-11-04 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200239845A1 (en) | Expanded nk cells | |
WO2019241549A1 (en) | Foxp3-expressing car-t regulatory cells | |
US12011461B2 (en) | Compositions and methods of hematopoietic stem cell transplants | |
US20210147800A1 (en) | Methods for producing regulatory immune cells and uses thereof | |
CA3098865A1 (en) | Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells | |
US20240009237A1 (en) | Method for cryopreserving engineered tregs | |
US20090304659A1 (en) | Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+ t cells | |
KR20130065657A (en) | New methods for isolating tr1 cells | |
Ring et al. | Expanded murine regulatory T cells: analysis of phenotype and function in contact hypersensitivity reactions | |
EP3430130B1 (en) | Methods of t cell expansion and activation | |
KR20130093083A (en) | Il-13 producing tr1-like cells and use thereof | |
WO2024107410A1 (en) | Cd39 selection for cytotoxicity of genetically engineered t regulatory cells | |
US20230167429A1 (en) | Compositions and methods of adamts13 chimeric autoantibody receptor cells | |
Williams et al. | Choice of resident costimulatory molecule can influence cell fate in human naïve CD4+ T cell differentiation | |
Hara et al. | Anergic lymphocytes generated by blocking CD28 and ICOS pathways in vitro prolong rat cardiac graft survival | |
US12037606B2 (en) | Methods of T cell expansion and activation | |
US20240117309A1 (en) | Methods for expanding t cell populations | |
CN116615532A (en) | Method for cryopreserving engineered tregs | |
WO2022258981A1 (en) | Multichain chimeric antigen receptor | |
Alnabhan | Study of the Activation of Peripheral Blood and Cord Blood Natural Killer Cells | |
Bloom | c12) United States Patent | |
Pedroza-Pacheco | Effect of umbilical cord blood regulatory T cells on natural killer cell differentiation and function | |
Kottoor | Regulatory T cells in human uveitis | |
EA044224B1 (en) | EXPANSION OF γδ-T-CELLS, COMPOSITIONS AND METHODS OF THEIR APPLICATION | |
Fry | Cell separation and cryopreservation of cord blood fractions for immunotherapeutic applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23892238 Country of ref document: EP Kind code of ref document: A1 |